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What Investigations Are Ordered in Patients 
with First-episode Psychosis? 
 
Allan Shefrin, M.D. (PGY2), Derek Puddester, M.D., Stephanie Greenham, Ph.D., 
Lise Bisnaire, Ph.D., Hazen Gandy, M.D. 
 
 
ABSTRACT 
Psychiatrists are often left with the dilemma of which investigations to order 
in adolescents presenting with a first episode of psychosis. Blood work, urine 
studies, and neuroimaging studies were tracked in 13 adolescents admitted 
with a diagnosis of first-episode psychosis over a 13-month period to the 
Children’s Hospital of Eastern Ontario. Variation was found in the amount of 
investigation ordered: 85% of patients received a drug screen; 54% a CT 
scan; 8% an MRI; 92% a CBC with differential; 92% electrolytes. 
Abnormalities of CT scans were detected in 2 patients (29%); in neither case 
did the result lead to a diagnosis of brain-lesion-related psychosis, nor did it 
affect the clinical care of the patient. This study highlights the need to develop 
clinical practice-guidelines for the workup of first-episode psychosis in 
adolescents. 
 
 
   First-episode psychosis has received considerable attention in both the pediatric 
and adult literature. One area of ongoing research is the degree to which children 
and adolescents require investigations to rule in or rule out non-psychiatric disease.   
According to the Diagnostic and Statistical Manual of Mental Disorders 4th Edition 
Text Revision (DSM-IV-TR), the diagnosis of schizophrenia and other psychotic 
illnesses require that criteria be met: where “the disturbance is not due to the direct 
physiological effects of a substance (e.g., of abuse or a medication) or a general 
medical condition”(1). Yet, in spite of these essential criteria, a standardized work-
up for first episode psychosis in children and youth is difficult to find. 
   Psychiatry associations and textbooks differ in their recommendations and often 
leave the decision to perform a test at the discretion of the attending physician. A 
summary of different guidelines can be found in Table 1. 
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Table 1: Summary of various guidelines for the investigation of patients with first episode psychosis 
Source Suggested Work-up 
Kaplan and Sadock(2) • Do: complete history and physical exam, urine toxicology screen, 
CBC, general chemistry screen, urinalysis 
• Consider: pregnancy test, ECG, MRI, CT, EEG 
Rutter and Taylor(3) • Do: CBC, ESR, electrolytes, renal function tests, glucose, calcium, 
magnesium, phosphate, liver enzymes, albumin, TSH, urinalysis, urine 
toxicology screen 
• Consider: neuroimaging 
Wiener(4) • Do: sexually transmitted disease screen 
• Consider other investigations as guided by history and physical exam 
American Psychiatric 
Association(5) 
• Do: history and physical exam, thyroid function tests, renal function 
tests, liver function tests, pregnancy screen, toxicology screen, syphilis 
screen 
• Consider: screening for HIV and hepatitis C, EEG/CT/MRI if indicated 
(new onset psychosis and atypical psychosis) 
American Association of 
Child and Adolescent 
Psychiatrists (AACAP)(6, 7) 
• Consider: CBC, chemistry, thyroid function tests, urinalysis, toxicology 
screen, infectious disease screens (if at risk)+, chromosomal analysis (if 
suggestive of developmental syndrome), neuroimaging (if evidence of 
neurologic dysfunction) 
CBC – complete blood count / ECG – electrocardiogram  
MRI – magnetic resonance imaging / CT – computed Tomography  
EEG – electroencephalogram / ESR – erythrocyte sedimentation rate 
TSH – thyroid stimulating hormone 
+ - high risk groups include: all adolescents with psychiatric symptoms; high risk adolescents (e.g.: runaways, 
delinquents, children of substance abusers); adolescents with changes in mental status or performance; adolescents 
with acute behavior changes; adolescents with recurrent accidents or unexplained somatic symptoms; adolescents 
for whom abstinence is to be monitored 
 
   There is much debate in the literature regarding the inclusion of neuroimaging in 
the standard work-up of children with first-episode psychosis. Some advocate a 
rule-in approach while others prefer a rule-out approach. The AACAP suggests 
that the use of CT and MRI be reserved for ruling out intracranial disease when 
suspected, and that they are of very low positive yield in the absence of clinical 
findings.(6, 7) Adams et al. conclude that routine endocrine and neuroimaging 
screening tests in first-onset adolescent psychosis are of little diagnostic utility and 
are not cost effective (8). They recommend that investigations be reserved for 
cases with symptoms suggestive of non-psychiatric pathology. Larson et al. 
concluded that CT scans should be used to rule in intracranial pathology as it has 
low yield in assisting clinical decisions in the absence of focal neurologic deficit 
(9).  
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   Yet a growing body of evidence suggests the potential value of neuroimaging for 
patients with first-episode psychosis. Various CT studies in adolescents and adults 
have found that patients with schizophrenia and other psychotic disorders exhibit 
ventricular enlargement, cortical atrophy, and cerebrospinal-fluid (CSF) 
circulation-disturbances (10-16). Magnetic resonance imaging is increasingly 
being used as a diagnostic and research tool in psychiatric illness. Various studies 
report gray matter deficits, increased CSF volume, decreased cerebral volume, 
thalamic abnormalities, and diminished size of the fusiform gyrus associated with 
psychosis (15-22). Jacobsen and Rapoport suggest that CT and MRI changes are 
not static but are affected by the duration or severity of illness and the modality 
and success of treatment (21).  
   Moreno et al. note that the interpretation of pediatric neuroimaging studies is 
difficult, owing to the variability of normal results secondary to age and body-size. 
They also note that diagnostic testing may be required in assisting patients and 
their families in gaining access to social and financial services (23).  
   Finally, many psychiatrists have informally reported cases of first-episode 
psychosis that have later been determined to result from a general medical 
condition (for example, intracranial tumor, developmental structural anomalies, 
metabolic disease, genetic disease, or seizure disorder). Thus, some psychiatrists 
advocate that a thorough workup should be done from a quality and risk 
management perspective. But few data, to date, support this perspective. 
 
METHODS 
   All psychiatry inpatients admitted for the 13 months from October 1, 2000 to 
October 31, 2001 were eligible for entry into the study database. Patients or their 
legal guardians (for those under 16 years of age) gave consent for their inclusion. 
The Research Ethics Board of the Children’s Hospital of Eastern Ontario (CHEO) 
approved the study. 
   Patients were excluded from this study if they had a seizure disorder, diabetes, 
anemia, migraine, endocrine disorder, or vitamin B12 deficiency. Patients 
readmitted to service were also excluded.  
   This process identified 174 patients, of which 13 presented with a primary 
diagnosis of psychosis. The remainder had mood or anxiety disorders. There were 
many more cases of psychosis, but they either presented with mood symptoms, or 
the psychosis was not evident at the time of admission. The 13 diagnosed with 
first-episode psychosis were age 14 to 17 years; 9 were male and 4 were female.  
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   Research assistants reviewed all inpatient charts and records and biological data 
was entered into the study database. Laboratory results were collected for patients 
and were divided based on whether tests were normal, abnormal, abnormally high, 
abnormally low and not ordered. Percentages of normal and abnormal results were 
calculated based on the number of tests ordered. With the exception of the CBC 
and urinalysis, which are required by the hospital for all admitted patients, tests are 
ordered at the discretion of the admitting psychiatrist. 
 
RESULTS 
   A neuroimaging study was ordered in 62% of patients (Table 2). Of these 8 
studies, an abnormality was detected in 2.  
 
 
Table 2: Results of neuroimaging studies for children and adolescents admitted to the Children’s 
Hospital of Eastern Ontario with a diagnosis of first-episode psychosis 
Test Norm Abnorm Not Ordered 
CT Head 5 2 6 
MRI 1 0 12 
EEG 8 0 5 
 
 
With respect to blood tests and urine toxicology, 92% of the patients were 
investigated (Tables 3 and 4). 
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Table 3: Laboratory investigations performed in 13 patients admitted to the Children’s Hospital 
of Eastern Ontario with a diagnosis of first-episode psychosis 
Test Normal Abnormal high Abnormal low Not Ordered 
WBC 8 2 2 1 
Neutrophils 9 2 1 1 
Hemoglobin 10 1 1 1 
Platelets 12 0 0 1 
TSH 11 0 0 2 
AST 7 0 0 6 
ALT 8 1 3 1 
Sodium 12 0 0 1 
Chloride 12 0 0 1 
Potassium 12 0 0 1 
Calcium 0 0 0 13 
Magnesium 5 0 0 8 
Phosphate 5 0 0 8 
Glucose 5 1 2 5 
Urea 8 0 2 3 
Creatinine 10 1 0 2 
 
 
Table 4: Toxin and drug of abuse testing in a sample of children and adolescents admitted to the 
Children’s Hospital of Eastern Ontario with a diagnosis of first-episode psychosis 
Toxin Screened Negative Positive Not ordered 
Acetaminophen 0 2 11 
Salicylates 0 2 11 
Ethanol 1 0 12 
Phencyclidine 11 0 2 
Benzodiazepines 8 3 2 
Cocaine 11 0 2 
Amphetamines 10 1 2 
Tetrahydrocannabinol 7 4 2 
Opiates 10 1 2 
Barbiturates 11 0 2 
 
   No patients were tested for sexually transmitted diseases. Two of the four female 
patients were tested for pregnancy. Both tests were negative. 
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DISCUSSION 
   There is considerable variation in investigations ordered by admitting 
psychiatrists for the workup of first-episode psychosis. Psychiatrists, overall, at the 
Children’s Hospital of Eastern Ontario tended to order more tests than are 
recommended by some authors, but vary greatly among themselves: 85% of 
patients received a drug screen, 54% received a CT scan, 8% received an MRI and 
92% received a CBC with differential and electrolytes. The variability may result 
from the lack of a clear practice guideline from an authoritative source or the risks, 
both medical and legal, of missing an alternative diagnosis. Some sources suggest 
the variability results from the lack of confidence psychiatrists have in their 
medical knowledge (8).  
   Attention should be given to differentiating which tests should be used for 
screening purposes and which tests for diagnostic purposes. In our study, 29% of 
patients who received a CT scan of the head had an abnormal result. One patient 
had a questionable mass in the right frontal lobe (not confirmed by MRI).  The 
other abnormal CT was suggestive of slightly large ventricles; MRI investigation 
was not done on this patient during the study period.  Neither abnormal CT result 
impacted on the patient’s diagnosis or treatment. As MRI becomes more accessible 
and affordable in Canada and a better understanding of the relationship between 
clinical and neuroimaging findings is attained, MRI may prove to be of utility in 
the clinical investigation of psychosis. This is also true of newer modalities such as 
positron emission tomography and single photon emission tomography. 
   It is widely understood that substance use is common in individuals with 
psychosis. Our study found that a considerable percentage of our subjects had 
clinically detectable levels of substances in their bodies. Of greater concern, 
however, is that 15% of patients were not screened for any substances at all, and 
92% were not screened for ethanol. Given that substances can cause psychosis, 
affect its prognosis, and represent a major comorbidity, it seems essential that these 
particular investigations be considered in all patients with a psychotic presentation. 
   Limitations of this study are clear. Our sample size is small, and correlative and 
causative conclusions cannot be drawn. We did not capture why certain studies 
were ordered in some patients and not others. Finally, the study was limited to 
biological investigations, and does not include the potentially valuable contribution 
of psychological and other evaluations. 
   Based on the results of this study, we can conclude that there is large variability 
in the ordering of investigations at CHEO for adolescents with first-episode 
psychosis. The findings of abnormal CT scans correlate with previous studies.  
Correlative and causative conclusions cannot be drawn with such a small sample 
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size. Therefore, more studies are needed to better standardize admission 
investigations and determine clinical correlations with laboratory findings. This 
will help guide further investigations such as cost/benefit analysis and monitoring 
of disease and treatment response. 
 
SOURCE INFORMATION 
From the University of Calgary (AS), the Department of Psychiatry, University of Ottawa (DP, 
HG), and the Mental Health Patient Service Unit, Children’s Hospital of Eastern Ontario (SG, 
LB). The authors thank the Psychiatry Associates of the Children’s Hospital of Eastern Ontario 
for funding the study, and wish to acknowledge Juliette Oleynik for her assistance with the 
manuscript. Direct inquiries to Dr. Puddester at puddester@cheo.on.ca 
__________________________________________________________________ 
 
REFERENCES 
1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition-Text Revision. Washington, D.C.: American 
Psychiatric Association Publishing Group 
 
2. Kaplan BJ, Sadock VA (2002). Kaplan and Sadock's Textbook of Psychiatry: 
Behavioral Sciences/Clinical Psychiatry. Philadelphia: Lippincott, Williams and 
Wilkins 
 
3. Rutter M, Taylor E (2002). Child and Adolescent Psychiatry. Oxford: Blackwell 
 
4. Wiener JM (1997). Textbook of Child and Adolescent Psychiatry. Washington 
D.C.: American Psychiatric Press 
 
5. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, 
Kreyenbuhl J (2004), ed. American Psychiatric Association: Practice Guideline for 
the Treatment of Patients with Schizophrenia.  Arlington, VA: American 
Psychiatric Association Publishing Group 
 
6. Zametkin AJ, Ernst M, Silver R. Laboratory and Diagnostic Testing in Child and 
Adolescent Psychiatry: A Review of the Past Ten Years. J Am Acad Child Adoles 
Psychiatry 1998; 37: 464-72 
 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  11 
7. McClellan J, Werry J, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein 
A, Kinlan J, Rue D, Shaw J, eds. Practice parameter for the assessment and 
treatment of children and adolescents with schizophrenia. J Am Acad Child Adoles 
Psychiatry 2001; 40(7 Supplement):4S-23S 
 
8. Adams M, Kutcher S, Antoniw E, Bird D. Diagnostic Utility of Endocrine and 
Neuroimaging Screening Tests in First-onset Adolescent Psychosis. J Am Acad 
Child Adoles Psychiatry 1996; 35:67-73 
 
9. Larson EB, Mack LA, Watts B, Cromwell LD. Computed Tomography in 
Patients With Psychiatric Illnesses: Advantages of a Rule-in Approach. Ann Intern 
Med 1981; 95:360-4 
 
10. Schulz SC, Koller MM, Kishore PR, Hamer RM, Gehl JJ, Friedel RO. 
Ventricular Enlargement in Teenage Patients with Schizophrenia Spectrum 
Disorder. Am J Psychiatry 1983; 140:1592-5 
 
11. Gewirtz G, Squires-Wheeler E, Sharif Z, Honer WG. Results of Computerized 
Tomography During First Admission for Psychosis. Brit J Psychiatry 1994; 
164:789-95 
 
12. Weinberger DR, DeLisi LE, Perman GP, Targum S, Wyatt RJ. Computed 
Tomography in Schizophreniform Disorder and Other Acute Psychiatric Disorders. 
Arch Gen Psychiatry 1982; 29:778-83 
 
13. Nyback H, Wiesel FA, Berggren BM, Hindmarsh T. Computed Tomography of 
the Brain in Patients With Acute Psychosis and in Healthy Volunteers. Acta Psych 
Scand 1982; 65:403-14 
 
14. MacDonald HL, Best JK. The Scottish First Episode Schizophrenia Study: VI. 
Computerised Tomography Brain Scans in Patients and Controls. Brit J Psychiatry 
1989; 154:492-8 
 
15. Hendren RL, De Backer I, Pandina GH. Review of Neuroimaging studies of 
child and adolescent psychiatric disorders from the past 10 year. J Am Acad Child 
Adoles Psychiatry 2000; 39(7):815-28 
 
16. Peterson BS. Neuroimaging in Child and Adolescent Neuropsychiatric 
Disorders. J Am Acad Child Adoles Psychiatry 1995; 34(12):1560-76 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  12 
 
17. Zipursky RB, Lambe EK, Kapur S, Mikulis DJ. Cerebral Gray Matter 
Volume Deficits in First Episode Psychosis. Arch Gen Psychiatry 1998; 55:540-6 
 
18. Frazier JA, Giedd JN, Hamburger SD, Albus KE, Kaysen D, Vaituzis AC, 
Rajapakse JC, Lenane MC, McKenna K, Jacobsen LK, Gordon CT, Breier A, 
Rapoport JL. Brain Anatomic Magnetic Resonance Imaging in Childhood-onset 
Schizophrenia. Arch Gen Psychiatry 1996; 53:617-24 
 
19. Ettinger U, Chitnis XA, Kumari V, Fannon DG, Sumich AL, O'ceallaigh S, 
Doku V, Sharma T. Magnetic Resonance Imaging of the Thalamus in First-episode 
Psychosis. Am J Psychiatry 2001; 158:116-8 
 
20. Lee CU, Shenton ME, Salisbury DF, Kasaim K, Onitsuka T, Dickey CC, 
Yurgelun-Todd D, Kikinis R, Jolesz FA, McCarley RW. Fusiform Gyrus Volume 
Reduction in First-episode Schizophrenia. Arch Gen Psychiatry 2002; 59:775-81 
 
21. Wood SJ, Velakoulis D, Smith DJ, Bond D, Stuart GW, McGorry PD, Brewer 
WJ, Bridle N, Eritaia J, Desmond P, Singh B, Copolov D, Pantelis C. A 
Longitudinal Study of Hippocampal Volume in First-episode Psychosis and 
Chronic Schizophrenia. Schizophr Research 2001; 52:37-46 
 
22. Jacobsen LK, Rapoport JL. Research Update: Childhood-onset Schizophrenia - 
Implications fot Clinical and Neurobiological Research. J Child Psychol and 
Psychiatry 1998; 39:101-13 
 
23. Moreno D, Burdalo M, Reig S, Parellada M, Ala AZ, Desco M, Baca-
Baldomero E, Arango C. Structural neuroimaging in adolescents with first episode 
psychosis. J Am Acad Child Adoles Psychiatry 2005; 44: 1151-7 
 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  13 
Psychogenic Stuttering Following a Gastric 
Bypass Operation: Case Report 
 
 
Deborah B. Raphael, M.D. (PGY2), Frank B. Schoenfeld, M.D. 
 
 
ABSTRACT 
We evaluated a 44-year-old female with bipolar affective disorder who 
presented with a 4-month history of severe stuttering and vague neurologic 
complaints.  She had lost 200 pounds after gastric bypass surgery two years 
before.  A childhood sexual- abuse victim, she admits that she “hid” in her 
weight for most of her life. Neurological evaluation of this patient was 
negative, and speech-pathology evaluation revealed highly atypical stuttering.  
Gastric bypass patients with a history of psychiatric disorders and childhood 
sexual abuse may be particularly vulnerable to somatoform disorders. 
 
 
   It has been widely reported that psychological complications are prevalent 
among the morbidly obese, although this point has been controversial (1). Glinski 
et al. elucidated that 70% of patients evaluated for gastric bypass surgery meet 
criteria for an Axis I disorder in the past or present and 36% for Axis II disorder 
(2).  In his study, he found that the lifetime prevalence of depressive disorders 
alone in this population was 56%, compared with the known lifetime prevalence of 
depressive disorders of about 17% in the general population.  Glinski noted that 
gastric bypass surgical candidates tend to use denial as a defense mechanism for 
avoiding negative emotions.  In keeping with this, overeating may serve as 
distraction from negative emotion in these individuals.  Somatization is another 
tendency in this particular population.   
   Some improvement of psychosocial functioning after surgical treatment of 
obesity has been reported (3).  Van Gemert et al. recently investigated the long-
term effects of surgically induced weight loss on the psychological functioning of 
morbidly obese patients.  They found that preoperative subjects had elevated 
values on negativism, somatization, and shyness scales on personality profiles; 
postoperatively, all these values normalized except somatization.  Thus, 
postoperative patients still were concerned about their health and still were inclined 
to react to psychological stress with physical complaints.   
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   Interestingly, Waters et al. found that the dramatic improvement in those mental 
health indices observed 6 and 12 months after gastric bypass surgery tends to erode 
to preoperative values two years after surgery, despite no weight gain (4).  As a 
possible explanation for this psychological regression, Waters’s group noted that 
for the first 12 postoperative months, patients have frequent clinic visits that taper 
off over the second year:  continued psychological support may remain essential 
for patients after bariatric surgery.  Moreover, patients with previously diagnosed 
Axis I disorders may require more support than those without.  When Halmi et al. 
evaluated 80 morbidly obese patients after gastric bypass, they found that those 
patients with documented psychiatric diagnoses had a significantly greater amount 
of psychosocial stress than those without those diagnoses (1).  
 
Impact of Past Sexual Abuse on Obesity and Outcome after Gastric Bypass 
   Sexually abused women are more likely than nonabused women to receive a 
psychiatric diagnosis during their lifetimes (5).  Women with a history of sexual 
abuse are also more likely to experience somatically based stress disorders and 
somatic disorders in general (6).  Moreover, multiple studies have found a 
relationship between childhood sexual abuse and extreme obesity.  Associations 
between childhood physical abuse and obesity, as well as between childhood 
neglect and obesity, also have been found (7), but core psychological reasons may 
differ.      
   A chart review of 131 patients by Gustafson et al. revealed that 60% of those 
who reported a history of sexual abuse were more than 50 pounds overweight, 
compared with 28% of age-and-sex-matched patients without a history of sexual 
abuse (5).  In addition, 25% of the abused group was found to be more than 100 
pounds overweight, compared with only 6% of controls. Researchers have 
proposed that the obesity may serve as protection from sexual advances from 
potential abusers.  Wiederman et al. showed that among obese women, those with 
a history of sexual abuse reported less body dissatisfaction and less weight 
fluctuation during adulthood compared with obese women who were not sexually 
abused, indicating that excess weight likely serves a particular function in sexual 
abuse victims (8).  Moreover, King, et al found in an outpatient weight-
management program that research subjects with a history of sexual abuse lost 
significantly less weight than those with no history of abuse (9).  It has been 
suggested that weight reduction in these patients may trigger anxiety symptoms as 
women approach the weight at which they were abused (5, 9).   
   Researchers have examined the correlation between sexual abuse history and 
weight-loss treatment failure.  In general, childhood sexual abuse survivors are less 
likely to be successful in maintaining weight loss after obesity treatment (10).  
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King et al. showed that obese individuals with a history of sexual abuse were more 
likely to have experienced psychological distress and to have lower self efficacy 
than their counterparts who were not abused, making compliance with an obesity 
treatment program exceedingly difficult in comparison.  It follows that a history of 
sexual abuse is an important pretreatment variable that may have a significant 
impact on obesity treatment outcome (9).  Although Buser et al. showed in their 
study that females with a history of sexual abuse were as successful with weight 
loss for the first 14 months after gastric bypass surgery as those without a history 
of sexual abuse, they do validate the necessity of additional support during and 
after weight loss interventions for individuals with a history of sexual abuse (11).    
 
Psychogenic stuttering 
   Stuttering is generally categorized as developmental or acquired.  Adult-onset 
stuttering is either a reemergence of a childhood (developmental) stutter or 
acquired, either neurogenic or psychogenic in nature.  The mechanism of 
developmental stuttering still is not well-understood: impaired neuronal 
communication, disturbed timing of activation in speech-relevant brain areas, and 
neuroanatomical abnormalities in the speech-language areas all have been 
implicated (12, 13).  Neurogenic causes of acquired stuttering include head injury, 
stroke, degenerative disease of the central nervous system, brain tumor, brain-
surgery, defects in the basal nuclei or thalamus, and drug-induced brain 
dysfunctions (14, 15).  In a case series by Roth, et al. involving 12 subjects with 
adult-onset stuttering that turned out to be psychogenic in nature, all initially 
required differentiation of neurologic from psychogenic stuttering through 
interdisciplinary collaboration.  All 12 subjects with psychogenic stuttering 
presented with other, concomitant neurologic-like complaints which also turned 
out to be nonorganic in etiology (16).   
   Psychogenic stuttering is well-described (15). The term “conversion reaction,” 
which refers to a process, through which psychological stress is converted into a 
somatic symptom, largely has replaced the older term “hysteria.”  Psychogenic 
stuttering, once known as “hysterical stuttering,” currently is considered a 
conversion disorder: an alteration in physical functioning that suggests a physical 
disorder but is an expression of psychological conflict (15). 
   The sudden onset of psychogenic stuttering is commonly preceded by an 
emotionally traumatizing event. Ten of the twelve patients that comprised Roth’s 
aforementioned case series had significant psychological disturbances surrounding 
the onset and development of the stuttering; the remaining two subjects were 
equivocal in this regard (16).  Mahr and Leith recently described a woman with an 
abuse history who was struggling with her decision to leave her husband when she 
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suddenly began to stutter (15). Deal has suggested that adult-onset non-
developmental and non-neurologically based stuttering usually has a sudden onset 
and is temporally linked to some form of psychological trauma or cumulative 
psychological stress (17). He reported an adult patient who had two discrete 
episodes of sudden-onset stuttering, each after an unsuccessful suicide attempt.  
   Mahr and Leith have presented a clear synthesis of the most up-to-date 
diagnostic schemes for psychogenic stuttering.  Defining criteria 1. a change in 
speech pattern suggesting stut-tering;  2. a relationship to psychological factors; 3. 
absence of organic cause.  Associated symptoms  1.  history of mental illness; 2. 
atypical features of stuttering, such as no secondary symptoms and no islands of 
fluency; 3. la belle indifference.  These authors have proposed that for stuttering to 
be diagnosed as a conversion reaction, all defining criteria must be met in addition 
to one associated symptom (15).  
   As opposed to developmental stuttering, for which studies have demonstrated a 
1:3 female:male ratio, psychogenic stuttering has been shown to occur in a 1:1 
female: male ratio (14). 
 
 
 
CASE REPORT 
   Ms. S is a 44-year-old Caucasian female who, two years after Roux-en-Y gastric 
bypass for morbid obesity, presented to us with a 4-month history of severe 
stuttering.  Neurologic symptoms were present also, which had been intermittent 
over the last year but worse over the last four months.  As a result of symptoms, 
she had stopped working.  Bipolar affective disorder had been diagnosed 15 years 
earlier, and, in addition, she reported childhood sexual abuse. 
   Ms. S has been hospitalized several times for bipolar illness.  One admission was 
for feeling “low” after separation from her first husband; another was for 
adjustment of her psychiatric medications. Lithium had caused a “toxic reaction,” 
valproic acid gave her “decreased touch sensation,” then carbamazepine was 
started without adverse effect. More recently, low dose quetiapine was also 
initiated.  Of note, stuttering began prior to the initiation of quetiapine. This patient 
has no history of substance abuse. 
   Past medical history is significant for obesity, which worsened after the births of 
her three children in her early twenties. Tubal ligation was carried out in her late 
twenties. The gastric bypass-operation mentioned above was accompanied by open 
cholecystectomy. 
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   Ms. S was thin as a child, but gained weight at puberty:  she was afraid to be 
around boys, and her developing body triggered memories of sexual abuse at age 
three by her father.  In her adolescence she avoided boys and tried to “hide” in her 
weight.  “A lot of therapy” over the years helped her deal with her childhood 
sexual abuse until she reached a point where she no longer psychologically 
“needed” the weight. 
   She has a Bachelor’s Degree, has completed graduate-level coursework, and has 
been employed in the field of career-development. She married in her early 
twenties and felt supported by her husband, although the intimate nature of their 
relationship was limited. Her three children, with whom she has a close 
relationship, are from this marriage. After 20 years of marriage, Ms. S and her first 
husband divorced, owing to his involvement with other women. Following the 
divorce, Ms. S proceeded with gastric bypass, which resulted in a loss of 200 
pounds. Over the next year, she found herself to enjoy dating, which involved 
physical intimacy with men.  About one year ago, she married her current husband, 
whom she describes as supportive, and with whom she is frequently physically 
intimate.  She does report that her new husband has told her that he likely would 
not have taken interest in her had she been overweight when they first met.  
   Two siblings suffer from a mood disorder and from substance abuse; alcoholism 
has been present in both parents.  Her father died from a brain tumor, and her 
grandfather had Parkinson’s disease.  
   She is pleasant and friendly, stuttering on many of her words.  She does not 
“mind the stuttering” and says with a smile that she “would not want to associate 
with people who would take issue with it anyway.”  She reports an active social 
life and has been initiating conversation with new people without self-
consciousness. Her “flippers,” which she calls her minimal bilateral arm fat, seem 
to be of more concern to her than is the stuttering. However, she does report that 
stuttering and occasional double vision interfere with her ability to work because 
she could not answer phones effectively or drive safely. As she describes matters, 
she has become highly dependent on her husband and her children to drive her to 
numerous medical appointments that now occupy much of her time.   
   Affect is labile during interviews; she is tearful when speaking about her bipolar 
disorder and the inability of medications to “fix it.” Throughout her life, she has 
felt that care providers have not believed her regarding her mood symptoms. This 
has frustrated her; she compares it to times in her childhood when her mother 
would not believe she was sick unless there was objective evidence, such as a 
fever. The patient cites low self-esteem as her biggest lifelong psychological 
problem, often feeling that she is “a bother” to people, particularly when she has 
depressed mood. She worries that her new husband may leave her, and she fears 
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gaining weight because “looks” are very important to him. Even so, things have 
been going well in the last year: a generally supportive marriage and a rewarding, 
albeit stressful, job. Ms. S has been told that her stuttering may be related to 
“anxiety,” but is confused because stress level has been much higher in other times 
of her life. Stuttering has never existed in the past. Moreover, she asserts, the only 
person she has ever known who stuttered is a character on a television program 
that she used to watch often.   
   She is unable to recount the details around the sudden onset of stuttering, but 
recalls that it started at the end of a vacation with her husband about one month 
prior to termination with her therapist of eight years; the latter was moving across 
the country. Ms. S now states that were she to stop stuttering, she might “miss it,” 
because it has become part of her “identity.”  She does not believe that she has 
received more attention since the stuttering began. She has stopped working, going 
on disability and enjoying her new status as a “domestic engineer.”   
   Extensive neurological workup was carried out for the following complaints:  
stuttering, continuous for 4 months, of sudden onset; double vision, about 20 
percent of the time, for 4 months; hand tremor, at rest, for one week; and memory 
and attention difficulties over the past month. Tremor was not observed during 
serial physical examinations, and unsteadiness with tandem gait and difficulty with 
balance were present on some occasions but not others; finger-nose-finger and 
heel-to-shin exercises were within normal limits. In sum, physical findings were 
inconsistent and elaborated. A thorough ophthalmic evaluation showed no 
abnormalities. MRA and MRI imaging was unremarkable, and testing was 
negative for infectious, endocrinologic, metabolic, and rheumatologic processes.   
   Speech evaluation revealed a moderate to severe dysfluency in about 50 percent 
of all spoken words, persisting when reading slowly. Certain behaviors were 
missing that normally accompany dysfluencies in adults: prolongations of sounds 
and secondary mannerisms (increased facial muscle or laryngeal tension). Neither 
discontinuation of quetiapine nor reduction in the dose of carabamazepine 
improved the patient’s symptoms.   
   When the symptoms initially arose, Ms. S had begun to schedule more medical 
and psychiatry appointments; this was shortly before termination with her therapist 
of eight years.  Since, she has seen psychiatrists at more than one facility and has 
sought multiple primary care visits. Chief complaints vary; one such is that of 
urinary symptoms (but they are unaccompanied by evidence of infection). Weekly 
psychotherapy sessions were initiated at our institution, but her care soon was 
transferred to a facility closer to her home. 
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DISCUSSION 
   Neurologic complications of bariatric surgical procedures do occur, neuropathy, 
encephalopathy, vitamin B12 deficiency, and thiamine deficiency, for example 
(18). Although we found no evidence of an organic basis for our patient’s 
symptoms, we did find from speech and psychological evaluations that, in addition 
to la belle indifference, nearly every criterion (see above) of Mahr and Leith for 
psychogenic stuttering was present. And multiple and vague quasi-neurologic 
symptoms accompanied the complaint of stuttering, just as Roth observed in all 
twelve of his psychogenic-stuttering subjects (16).  
   Accepting the diagnosis of a conversion reaction in this patient, what 
unconscious psychological conflict does Ms. S express through her stuttering? A 
number of possibilities exist. A therapist of eight years recently moved away. This 
abrupt termination took place alongside the recent, steady diminution of this 
patient’s medical appointments since the bariatric operation, cutting her contact 
with care providers significantly. As mentioned, Waters has noted an erosion of 
mental health about two years after gastric bypass surgery (4). This also is when 
some patients tend to regain weight. Ms. S fears gaining weight because she 
worries that her husband will leave her if she becomes obese. On the other hand, as 
a sexual abuse survivor, without the protection of obesity she may be especially 
vulnerable to unconscious fear (9). Somatic symptoms produce the nurturing care, 
the protection, of family and healthcare workers. She can cite many instances in 
her life when she has tried to communicate her needs and has not been believed; 
stuttering is noticeable; it demands attention. And, given the involvement of the 
oral cavity in stuttering, one might wonder if the symptom represents a 
displacement of guilt or fantasy about either oral sex or eating. These would be 
topics to further explore in dynamically oriented psychotherapy. 
   Could the emergence of Ms. S’s somatic symptoms have been prevented? A 
history existed of both bipolar affective disorder and childhood sexual abuse: one 
could argue that she was predisposed to psychological deterioration after her 
identity-altering surgery. According to both Waters and Buser, additional and 
continued psychological support should be offered to patients following bariatric 
operations, particularly those with a history of a psychiatric disorder and a history 
of childhood sexual abuse (4, 11).  
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Psychiatric Diagnoses in Patients with 
Williams Syndrome and Their Families 
 
Janet C. Kennedy, M.D. (PGY1), David L. Kaye, M.D., Laurie S. Sadler, M.D. 
 
ABSTRACT 
Williams Syndrome (WS) is a genetic disorder associated with mental 
retardation (MR) and a distinct behavioral phenotype including a friendly 
and outgoing personality. This population, like others with MR, has been 
reported to have an increased rate of symptoms of mental illness; however, 
few studies have used DSM-IV criteria to quantify specific psychiatric 
diagnoses in WS and  the prevalence of psychiatric illness in relatives of 
individuals with WS and the possible relationship between family and patient 
diagnoses is currently unknown.   
Methods: Twenty-one families participated; the patients’ average age was 16 
years. DSM-IV diagnoses were applied by using the Anxiety Disorders 
Interview Schedule (ADIS, Parent and Child Versions) and the Family 
History Screen.   
Results: A diagnosis from the ADIS was applicable to 13 patients (62%), and 
in 16 patients (76%) a diagnosis was applicable in their first-degree family 
members.  Ten patients (48%) had some form of anxiety, specific phobia 
being the most common. Three patients (14%) had major depressive disorder 
and 9 patients (43%) had attention-deficit/hyperactivity disorder (ADHD). 
The presence of anxiety or mood disorders in patients with WS and the 
presence of these disorders in their family members were unrelated.  
Conclusions:  Patients with WS have a high prevalence of anxiety disorders 
and of ADHD.  The presence of psychiatric disorders in WS did not appear to 
have a significant relationship to family history of psychiatric disorders, 
consistent with the hypothesis that the specific genetic alteration in WS causes, 
or contributes to causing, the anxiety disorders and the ADHD that are so 
common in the disorder.  
 
 
   Populations with mental retardation (MR), especially those with known genetic 
alterations, offer a window into the effects of genes on determining cognition and 
behavior.  Populations with MR are known to have increased rates of emotional 
distress and mental illness (1, 2).  While estimates vary, the prevalence of 
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psychiatric disorders in individuals with MR is reported as three to four times than 
in the general population (3). Of children with MR living in the community, 20-
35% have been found to have a comorbid mental illness (2).  Reported rates of 
psychiatric diagnoses in this population have varied, ranging from 12% to 42% (2).  
More recent studies demonstrate the prevalence of psychiatric disorders in MR 
children to be 33-40% (4, 5).  When DSM-IV criteria are used, 39% of a cohort of 
mentally retarded children have a diagnosable mental illness (6)  
   Williams syndrome (WS) serves as a prototype for studying the relationship 
between genetics and behavior because affected patients have a strikingly similar 
behavioral phenotype. WS results from a deletion that includes the elastin gene on 
chromosome 7q11.23 and occurs in 1 in 10,000-20,000 births (7, 8).  Most cases 
result from a new mutation.  The associated mental retardation generally results in 
an IQ between 41 and 80 (8).  Other characteristics of WS include short stature, 
specific facial features, hyperacusis, and cardiovascular defects.  Individuals with 
WS demonstrate relative strengths in auditory rote memory and verbal ability.  
Compared to other mentally retarded individuals with similar IQ, children with WS 
speak more fluently, possess larger vocabularies, and are better conversationalists 
(8).  Additionally, these patients are highly sociable, an affability sometimes 
described as a “cocktail party personality”: talkative, overfriendly, and outgoing; 
they notably lack stranger anxiety.   
   Individuals with WS frequently exhibit psychiatric symptoms: generalized 
anxiety and worries, negative mood, and sensitivity to criticism. Behavioral and 
emotional disturbances have been reported in up to 80% of children with WS, 
much higher than in other mentally retarded populations (9). They have 
significantly more fears as well as a wider range of frequently occurring fears as 
compared to other mentally retarded populations, and also have an increased 
prevalence of anticipatory anxiety (10). 
   Even so, few studies have used DSM-IV criteria to quantify specific psychiatric 
diagnoses.  Additionally, there is little research examining the possible relationship 
between family history of psychiatric illness and psychiatric diagnoses in WS 
patients.  This study aims to identify the prevalence and nature of psychiatric 
disorders in patients with WS using standard DSM-IV criteria.   The study also 
aims to determine the prevalence of psychiatric disorders in first-degree relatives 
of WS patients and examine the possible relationship between family history of 
psychiatric illness and patient symptomatology.  We hypothesized that if mood, 
anxiety, or ADHD disorders were a part of the WS behavioral phenotype in and of 
itself, there would be no relationship between the presence of those disorders in 
patients and their presence in family members.  
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METHODS 
   All patients age 7 years or older who have been evaluated at the Williams 
Syndrome Clinic of Women and Children’s Hospital of Buffalo, NY were 
contacted by mail and telephone to participate in the study.  The Williams 
Syndrome Clinic is a multidisciplinary center that regularly evaluates patients from 
a large geographic area.  Patients were excluded from the study if a biological 
parent was not the primary caregiver.  Twenty-one of 28 eligible families agreed to 
participate.  All were Caucasian.  All children with WS lived at home with one or 
both parents. They ranged in age from 7-28 years (mean 16 years); 14 of the 21 
patients were female.  All patients had WS that was confirmed by fluorescence in 
situ hybridization (FISH) analysis. Seven patients had currently or previously taken 
one or more pharmacologic agents for treatment of psychiatric or behavioral 
symptoms. 
 Patients and both parents, when available, were interviewed in their own 
homes by a single examiner (JCK).  Seventeen families (81%) had both parents 
present at the time of interview.  Subjects and parents received information on the 
nature of the study and the assessment tools; subjects and the parents that were 
present gave written informed consent. The study methods were approved by the 
Institutional Review Board of Women and Children’s Hospital of Buffalo.  Parent 
and child responses and diagnoses were reviewed by a child and adolescent 
psychiatrist (DLK). 
 
Measurements 
   The Anxiety Disorders Interview Schedule (ADIS) is a standardized semi-
structured interview that uses DSM-IV criteria to assess for 14 psychiatric 
disorders in children and adolescents, including anxiety, specific phobia, MDD, 
and ADHD (11).  The ADIS was administered separately to the parents and the 
individual with WS (using both Parent and Child Versions) to arrive at a single 
combined score.  In order for a diagnosis to be assigned, symptom-criteria must be 
met and must interfere with functioning.  An impairment in functioning is defined 
by a minimum score of 4 on a scale of 0 to 8, as rated by both the subject and the 
parents in answer to the questions: “How much has [the problem] messed things up 
for you with friends, in school, or at home?  How much does it stop you from 
doing things you would like to do?” 
   The Family History Screen (FHS) is a semi-structured interview assessing 
lifetime history for 15 psychiatric disorders in subjects and first-degree relatives 
(parents and siblings) (12).  The FHS was administered separately to each 
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biological parent. Diagnoses queried included anxiety, specific phobia, MDD, and 
ADHD. 
 
Data Analysis 
   Descriptive analyses were used for the prevalence and distribution of psychiatric 
diagnoses in the study population.  The association between patient and family 
history of selected disorders was analyzed using Fisher’s exact tests for 
contingency tables.  Disorders examined in subjects and family members were 
MDD, any anxiety, specific phobia, and ADHD, as these were expected to be the 
most prevalent based on previous studies (1, 13).  Because anxiety and depression 
may occur together, analyses were also performed for any mood or anxiety 
disorder.  Fisher’s exact test was chosen over the Chi-square test for independence 
because of the small cell- frequencies (expected cell frequencies < 5) in all of the 
2x2 contingency tables.  For Fisher’s exact test, the null hypotheses of 
independence was performed at a 0.05 significance level.  All of the statistical 
analyses are performed on SAS version-9. 
 
 
RESULTS 
DSM-IV Diagnoses in WS population   
   Thirteen of 21 subjects (62%) had at least one DSM-IV diagnosis (Table 1). The 
most common were: any anxiety disorder (48%), specific phobia (43%), ADHD 
(43%), and generalized anxiety disorder (GAD) (24%). Major depressive disorder 
(MDD) was found in 3/21 (14%) of the patients.  There were no significant 
differences with regard to sex or age for any diagnosis.  More than one diagnosis 
was present in 33% of the sample; 24% had more than 2 diagnoses. 
 
Phobias.  Specific phobia was present in 43% of patients and was the most 
common type of anxiety disorder, present in 9 of the 10 subjects with an anxiety 
diagnosis.  The most common types of specific phobia were animal, 
thunderstorm/lightning, and loud noises.  Seven of the 9 patients had multiple 
phobias. No subject had social phobia.  
   ADHD.  Of the subjects with ADHD, 8 of 9 were of the inattentive type, 1 was 
the combined type, and none were of the hyperactive-impulsive subtype.  
   ADIS diagnosis requires a functional interference score greater than 4 out of 8.  
Many more of these subjects met a symptom-criteria for diagnosis but did not meet 
the requirement for functional interference.  Fifteen subjects (71%) demonstrated 
symptoms of specific phobia but only 9 (43%) had significant impairment in 
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functioning.  Two additional subjects met criteria for GAD, and 4 additional 
subjects met criteria for ADHD but again did not meet the functional interference 
requirement. 
 
Table I. Diagnoses in Williams Syndrome Patients 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family History of Psychiatric Diagnoses   
   Seventy-six percent of subjects had first-degree relatives with any diagnosis on 
the FHS.  The ADIS diagnoses used in statistical analysis were: MDD, any 
Diagnosis n % 
Any Diagnosis 13 62 
  Any Anxiety Disorder 10 48 
     Separation Anxiety 1 5 
     Social Phobia 0 0 
     Specific Phobia 9 43 
     Panic Disorder 1 5 
     Agoraphobia 1 5 
     Generalized Anxiety Disorder 5 24 
     Obsessive-Compulsive Disorder 0 0 
     Post Traumatic Stress Disorder 1 5 
  Dysthymia 2 10 
  Major Depressive Disorder 3 14 
  Any ADHD 
     ADHD-Inattentive 
     ADHD-Impulsive 
     ADHD-Combined 
9 
8 
0 
1 
43 
38 
0 
5 
  Conduct Disorder 0 0 
  Oppositional Defiant Disorder 1 5 
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anxiety, specific phobia, and ADHD.  Variables examined were: presence or 
absence of a diagnosis in the subject, and presence or absence of the diagnosis in 
first-degree relatives. 
   Of the WS subjects with MDD, 2 of 3 had a first-degree family history of MDD; 
of those without MDD, 6/18 had a first-degree family history of MDD. There was 
no statistically significant association between family history of MDD and subject 
MDD (p = 0.5308).  
   Of the WS subjects with any anxiety diagnosis, 4/10 had a first-degree family 
history of anxiety; of subjects with no anxiety diagnosis, 6/11 had a first-degree 
family history of anxiety. There was no statistically significant association between 
family history of anxiety and subject anxiety (p = 0.6699).  
   Of the WS subjects with a mood or anxiety disorder, 6/11 had a first-degree 
family history of a mood or anxiety disorder; 7/10 subjects without a mood or 
anxiety disorder had a first-degree family history of a mood or anxiety disorder. 
There was no statistically significant association between family history of mood 
or anxiety disorders and subject mood or anxiety disorders (p = 0.6594). 
   No WS subject with specific phobia had a family history of specific phobia (0/9).  
Two subjects out of 12 with no diagnosis of phobia had a family history of specific 
phobia.  There was no statistically significant association between first-degree 
family history of specific phobia and subject specific phobia (p-value = 0.4857).  
   Of the subjects with ADHD, 2/9 had a first-degree family history of ADHD; 1/12 
without ADHD had a first-degree family history of ADHD. There was no 
statistically significant association between family ADHD and subject ADHD (p-
value = 0.5534). 
   In summary, no statistically significant association was found between family 
history of MDD, any anxiety, specific phobia, and ADHD and the presence of 
these disorders in WS subjects. 
 
DISCUSSION 
   The WS patients of this report have a higher prevalence of psychiatric disorders 
compared with other populations of MR children and adults (62% vs. 39%) (6), as 
well as compared with cognitively normal children (62% vs. 12%) (14). An 
increased prevalence of psychiatric diagnoses was observed even when impairment 
in functioning was required for diagnosis.  The rates for specific diagnoses would 
have been higher if not for this requirement (e.g., 71% vs. 43% for specific 
phobia).  The use of impairment in functioning is a distinctive aspect of this study 
and rarely has been used in previous studies.  
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   Anxiety was the most prevalent diagnosis in the study population: 10/21 patients 
(48%).  Five of these patients (24%) had GAD while 9 of 10 (43%) met diagnostic 
criteria for specific phobia.  Types of phobias included animals, thunderstorms, 
loud noises, and high places.  While some phobias may be attributed to the 
hyperacusis described in WS, not all phobias were related to sound.  Most patients 
with phobias to loud noises also had phobias that were not sound-related. Despite 
the frequent occurrence of phobias, no patient had social phobia, consistent with 
the hypersociability that characterizes WS. This strong desire for social interaction 
appears to be an exception to the other anxieties observed in WS patients. 
   Previous studies of anxiety in WS have yielded similar results. Dykens reported 
excessive worry in 57% of children and adults with WS (10).  However, using a 
DSM-III-R parent interview, only 16% of patients met diagnostic criteria for GAD, 
similar to the 24% observed in this study.  Similarly, while 96% of patients 
reported persistent anxiety-producing fears, only 35% met diagnostic criteria for 
specific phobia (10).  A multisystem study of WS adults that used the ADIS 
reported anxiety disorders in 65% of patients, with specific phobia being the most 
common subtype of anxiety (15). The present study further supports that anxiety 
disorders, especially specific phobia, appear to be distinctive behavioral findings in 
patients with WS. Of interest, despite frequent preoccupations in patients with WS, 
no patient met DSM-IV criteria for obsessive-compulsive disorder. 
   Nine patients (43%) met criteria for ADHD, with 8 of the 9 having the 
inattentive type.  This is higher than rates reported in studies of other MR 
populations (4-21%) (1,13).  Features of inattention and distractibility have 
previously been described in WS (16). Distinguishing ADHD from other features 
of mental retardation is, admittedly, difficult. For example, it may be that the 
hyperacusis in WS or some other attribute of MR contributes to distractibility.  
Alternatively, it may be that inattention is part of the behavioral phenotype of WS. 
   Only three patients (14%) were found to have a history of MDD.  This appears 
consistent with estimates in the normal pediatric population of 8-20% (17) and in 
other studies of MR children of 4-10% (1).   
   Previous studies have not assessed the prevalence of psychiatric disorders in 
relatives of WS patients.  Although psychiatric illness was common in first-degree 
relatives of the patients of this study (76% with any diagnosis), comparison of 
specific diagnoses between patients and relatives failed to yield a statistically 
significant association for any diagnosis.  The data were analyzed to detect any 
relationship between the presence or absence of specific psychiatric disorders in 
family members and the presence or absence of each disorder in the WS patient.  
The absence of any significant relationship with family history is consistent with 
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our hypothesis that the presence of psychiatric illness in WS may be caused by the 
specific chromosomal deletion rather than the genetic contribution implicit in the 
family history of psychiatric illness.  However, the statistical analyses performed 
were limited due to the small frequencies of the outcome measurements.  
Extrapolation of the data from the Fisher’s exact test indicates that at least 60 
subjects would be needed to find a statistically significant relationship among the 
variables.  Therefore, while the results are suggestive that there may be a 
chromosomal link between psychiatric illness and WS, the data are insufficient to 
prove this conclusion. 
Additional study limitations should be mentioned.  As in any clinical research, it is 
important to acknowledge the possibility of non-response bias, specifically in this 
study that the families who agreed to participate may have had a different 
incidence of psychiatric disorders compared with those who declined.  
Additionally, there is an inherent recall bias in that families may under or over-
report psychiatric illness in their family members in the presence of the 
interviewer.  Findings could be enhanced in future studies by using a comparison 
group in the study itself, such as other MR populations.  This would have been 
valuable because this study included the investigation of family history of 
psychiatric illness as well as the use of strict DSM-IV criteria in subjects, features 
not extensively investigated previously and therefore difficult to use in comparison 
analysis.   
   An important implication of this study is that greater attention needs to be 
devoted to recognizing psychiatric problems in individuals with MR, especially 
those with WS.  Clinicians need to recognize the increased prevalence of specific 
disorders and to monitor for these illnesses as part of routine medical care, 
especially GAD, specific phobia, and ADHD.  The psychiatric findings in patients 
with WS may provide insight into the genetic determinants of behavior and 
psychiatric illness in more generalized populations; therefore, additional research 
should continue to further investigate these relationships.  Future research is also 
needed to systematically evaluate different treatments for anxiety disorders and 
ADHD in WS and other MR populations. 
 
 
SOURCE INFORMATION 
From the Massachusetts General Hospital, Boston, MA (J.C,K.) and the McLean Hospital, Belmont, MA (J.C.K.), 
Adult Psychiatry Residency Programs; the Division of Child and Adolescent Psychiatry, Department of Psychiatry, 
SUNY Buffalo, NY (D.L.K.) and Women and Children’s Hospital of Buffalo, NY (D.L.K.); and the Division of 
Genetics, Department of Pediatrics, SUNY Buffalo, NY (L.S.S.) and The Williams Syndrome Clinic of Women and 
Children’s Hospital of Buffalo, NY (L.S.S.). The authors thank the study participants and their families who gave so 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  30 
generously of their time in order to further the understanding of Williams Syndrome, and  thank Tulay Koru-Sengul 
for her statistical assistance. Direct inquiries to Dr. Kennedy: jckennedy@partners.org                                    .      
 
_____________________________________________________________________________________________ 
REFERENCES 
1. Dykens EM. Psychopathology in children with intellectual disability. Child 
Psychol Psychiatry 2000; 41: 407-17 
 
2. Singh NN, Sood A, Sonenklar N, Ellis CR. Assessment and diagnosis of mental 
illness in persons with mental retardation. Behav Mod 1991; 15:419-43 
 
3. American Psychiatric Association (2000). Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American 
Psychiatric Publishing Inc. 
 
4. Einfeld SL, Tonge BJ. Population prevalence of behavioural and emotional 
disturbance in children and adolescents with mental retardation. 2. Epidemiological 
findings. J Intellect Disabil Res 1996; 40:99-109 
 
5. Stromme P, Diseth TH. Prevalence of psychiatric diagnoses in children with 
mental retardation: data from a population-based study. Dev Med Child Neurol 
2000; 42: 266-70 
 
6. Dekker MC, Koot HM. DSM-IV disorders in children with borderline to 
moderate intellectual disability. I: prevalence and impact. J Am Acad Child 
Adolesc Psychiatry 2003; 42:915-22 
 
7. Mervis CB. Williams Syndrome: 15 years of psychological research. Dev 
Neuropsychol 2003; 23:1-12 
 
8. Lashkari A, Smith AK, Graham JM, Jr. Williams-Beuren syndrome: an update 
and review for the primary physician Clin Pediatr  1999; 38:189-208 
 
9. Udwin O, Yule W, Martin N. Cognitive abilities and behavioural characteristics 
of children with idiopathic infantile hypercalcaemia. Child Psychol Psychiatry 
1987; 28:297-309 
 
10. Dykens EM. Anxiety, fears, and phobias in persons with Williams syndrome. 
Dev Neuropsychol 2003; 23:291-316 
 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  31 
11. Silverman WK, Albano AM (1996). Anxiety Disorders Interview Schedule for 
DSM-IV, Child and Parent Versions. San Antonio, TX: Psychological Corporation 
 
12. Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. 
Brief screening for family psychiatric history. Arch Gen Psychiatry 2000; 57:675-
82 
 
13. Szymanski L, King BH. Practice parameters for the assessment and treatment 
of children, adolescents, and adults with mental retardation and comorbid mental 
disorders. American Academy of Child and Adolescent Psychiatry Working Group 
on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999; 38 (12 Suppl):5S-
31S 
 
14. Costello EJ, Egger H, Angold AJ. Ten-year research update review: the 
epidemiology of child and adolescent psychiatric disorders: I. methods and public 
health burden. J Am Acad Child Adolesc Psychiatry 2005; 44:972-86 
 
15. Cherniske EM, Carpenter TO, Klaiman C, Young E, Bregman J, Insogna K, 
Schultz RT, Pober BR. Multisystem study of 20 older adults with Williams 
syndrome. Am J Med Genet 2004; 131:255-64 
 
16. Greer MK, Brown FR 3rd, Pai GS, Choudry SH, Klein AJ. Cognitive, adaptive, 
and behavioral characteristics of Williams syndrome. Am J Med Genet 1997; 
74:521-5 
 
17. Satcher DS. Executive summary: a report of the surgeon general on mental 
health. Pub Health Rep 2000; 115:89-101 
 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  32 
No More Cuts: The Curious Fate of Self-
Mutilation in Its Development 
 
Zhabiz Kazeminezhad, M.D. (PGY4), Salman Akhtar, M.D. 
 
 
ABSTRACT 
In this article, we present descriptions of four young women with relatively 
severe personality disorders. All four were in psychodynamic psychotherapy 
and all had the symptom of self-cutting.  During their treatment, it became 
evident that their self-cutting had undergone a transformation and a new 
symptom had appeared in its place. In three, self-cutting was substituted by 
behaviors that we might call “cutting equivalents” and, in the fourth, by an 
enhanced self-reflective attitude and by journal-writing. We suggest that 
symptom-replacement for self-cutting may be common in its developmental 
course or in its course as it becomes influenced by psychotherapy, and that the 
replacement is sometimes, perhaps often, salutary.   
 
 
   Approaching severe personality disorders psychodynamically has its pros and 
cons (1-3).  On the one hand, it provides a deeper and more specific understanding 
of the patient, one in which his or her symptoms are seen as intricately bound with 
constitutional givens, early childhood experiences, and unconscious fantasies. On 
the other hand, if symptoms are end-products of a ‘trauma-fantasy-wish-defense’ 
sequence, any effort aimed simply at symptom-reduction is conceptually suspect 
and has practical risk.  Psychodynamic models of etiology compel the prediction 
that removing a manifest disturbance might be undesirable, if the underlying issues 
responsible for it remain unresolved.  This consideration acquires greater 
significance in cases of severe personality disorders (e.g., borderline, schizoid, 
antisocial, paranoid), which in some instances appear nearly intractable. The best 
outcome could be that a new, less toxic symptom replaces the older, more toxic 
one. Of course, if the former takes sublimatory or even “pseudo-sublimatory” form 
(1), the outcome can be regarded as not bad after all.  
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CASE REPORTS 
Case 1 
   Inez is a 24-year-old nursing student with a history of self-cutting that began at 
age sixteen, dwindled around age eighteen, and stopped completely by age twenty-
one.  The onset of cutting coincided with her family’s moving in with her new 
step-father.  Inez felt she never belonged in that house and was like an unwanted 
guest. She cut herself when the feeling of being unwanted mounted and became 
unbearable. The urge to cut was more frequent, but she was able to restrict the act 
to once a month for fear of getting caught. 
   Inez was born to adolescent parents of different racial origins who were forced 
into a marriage because of the pregnancy. Inez’s mother soon began an 
extramarital affair with a man who would later became Inez’s stepfather; the 
parents divorced when she was twelve.  Inez was aware of the infidelity, for her 
mother often had taken her to the house of the mother’s lover before the divorce. 
She often had told Inez, from the latter’s early childhood, that Inez was unwanted 
and the cause of her mother’s unhappiness.  Whenever they were separated, Inez 
found herself afraid that her mother would never return. 
   Inez began to work in a tattoo parlor at age eighteen.  As an employee, she was 
able to get tattoos for free and often took advantage of this perk.  Although she said 
that the pain of the needles bothered her, she found great pleasure in receiving the 
tattoos. She discovered even more pleasure in displaying them on her body.  
Interestingly, the self-cutting decreased soon after she began working in the tattoo 
parlor. Within two years, she had stopped cutting herself altogether, although she 
continued to obtain new tattoos regularly. 
 
Case 2 
   Emily is a 23-year-old graduate student with a history of self-cutting that began 
at the age of fourteen and ended at eighteen.  She began cutting herself soon after 
the onset of her menses, which she experienced as traumatic. Mostly she cut on her 
arms and forearms, but after her cutting was discovered by her friends she began 
cutting on her belly and thighs instead. Cutting relieved the tension that would 
follow on an argument with her mother. During childhood and adolescence Emily 
believed that her mother did not love her.  Frequent, heated arguments took place, 
during which Emily would tell her mother that she hated her. 
   Emily had been born into a working class Catholic family that had traditional 
views regarding household gender-roles. Beginning at age ten, she was expected to 
begin preparing dinner before her parents came home; two older brothers had no 
such responsibilities.  Because of this difference in treatment, she often felt that her 
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mother did not love her as much as she loved her brothers. She did not want to 
grow up to be a woman.  Menarche was quite disturbing to her and was soon 
followed by the onset of self-cutting. 
   The cessation of cutting at eighteen seemed related to substitution of 
masturbation three times daily, a habit that continues to the present.  Much like the 
self-mutilation of her adolescence, Emily considers the masturbation to be a source 
of tension release.  During masturbation, she often fantasizes about being raped or 
otherwise forced into sexual activity: it is as if the tormented soothing of cutting 
had been replaced by the sadomasochistic erotic fantasy. 
 
Case 3 
   June is a 29-year-old, unemployed African-American woman with a long history 
of self-cutting.  Cutting began at age eight soon after being sexually abused by a 
friend of her parents.  The sexual molestation occurred many times but 
spontaneously ceased after about a year.  June would cut herself immediately after 
an episode of molestation because she felt she needed to, literally and physically, 
feel her emotional pain: “Talking about it wasn’t intense enough.” Cutting lessened 
in adolescence when she began to act out in school, skipping classes, fighting with 
classmates, and having indiscriminate sexual encounters with boys.  After high 
school, June eventually became monogamous and stopped self-cutting.  About five 
years later, it started again when a male companion had become physically abusive 
towards her.  After leaving that relationship, the behavior again ceased.  However, 
since then, June finds that affectionate sexual play is not satisfactory to her.  
During sex, she likes to pretend that she is being beaten or raped, a form of self-
abuse that is possibly akin to cutting. 
   Her parents were intravenous drug abusers who lived together at the time she 
was born. Soon after, the father contracted HIV and eventually passed it on to the 
mother.  The latter was severely verbally abusive to June. The father has since 
died. Her relationship with her mother remains ambivalent. To date, whenever 
mother and daughter argue, June finds that she wants to scratch herself.  Blood is 
not drawn, nor is that her intent.   
   June’s self-cutting relieved tension, as it almost always followed the mother’s 
verbal abuse.  It also seemed to be related to an inability to feel satiated 
emotionally by verbalizing pain. Over time, she replaced cutting herself with acts 
of physical aggression toward others, sexual promiscuity, and masochistic sexual 
fantasies.   
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Case 4 
   Rebecca is a highly intelligent 22-year-old African-American college student 
with a record of academic excellence dating back to childhood. She also has a 
history of self-cutting that began at age twelve and ended at fifteen. She recalls that 
the impetus for this behavior began with reading a magazine article written about a 
young woman who had had experiences much like her own and had found 
emotional release through the act of self-cutting. At a younger age, Rebecca had 
experienced many events that left her anxious and tense. First, she had been 
sexually abused by her grandmother as a young child. Next, her parents divorced 
when she was twelve.  After the divorce, her father made no attempt to contact the 
family again.  Rebecca had been closest to her father; he had given much love, 
attention, and intellectual encouragement. 
   She found the razor cutting across her skin particularly pleasurable. She also 
enjoyed watching blood being expressed from the site of the cut.  As she 
discovered such pleasures, she cut herself habitually whenever she was sad, 
especially if the sadness was accompanied by an urge to cry. Cutting decreased 
when she began drinking alcohol, but did not stop until age fifteen. Several factors 
seem responsible for its cessation. She was discovered by family members, who 
shamed her for her behavior. She also began writing in a journal about her personal 
experiences and mental pain. Journal writing became an increasing part of her 
personal life. During these years, whenever she felt the urge to cut, she would go to 
the bathroom and intently look at the collection of used and bloodied razors; this 
substituted, she reported, for the literal act of self-cutting. 
 
DISCUSSION 
   A symptom neither arises nor is resolved independently of other conscious and 
unconscious aspects of the patient’s mind and the relation between the patient and 
the therapist.  With such proviso, we want to assert that all four patients presented 
here demonstrate the phenomenon of symptom-replacement.  Self-cutting is 
replaced by receiving tattoos (Inez), sadomasochistic sexual fantasies (Emily), 
fighting and provocative role-playing during sex (June), and wistfully looking at 
bloodied razors (Rebecca). An explicit form of self-mutilation is thus transformed 
into its “aim-inhibited” versions (4).  Yet important differences in the four cases 
can be discerned.  Inez, the patient with the most traumatic background, replaced 
self-cutting by another assault on her body, tattooing. Emily and June channeled 
self-destructive propensities away from body into mental life, binding their 
masochism with libido to create erotic sadomasochistic fantasies. Rebecca showed 
a mixed outcome. On the one hand, masochism moved from body to mind 
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(although unerotically).  On the other hand, she began to write about the internal 
distress that had given rise to self-cutting in the first place, showing ego growth 
and an adaptation akin to sublimation.   
   The difference in the outcome of self-cutting in these patients is multiply-
determined (5), just the way the symptoms themselves were.  Three variables 
readily come to mind. First is the intensity of childhood trauma.  Second is the 
degree of constitutional resilience, present in one instance in the form of high 
intelligence. The third is the presence of a reasonably sustained good object 
relationship during childhood. Among our patients, the one most traumatized could 
only advance from a naked form of violence against her body to becoming 
tattooed.  On the other end of the spectrum is the patient who had received much 
love from her father in early childhood and also had high intelligence; she went 
from cutting to merely looking at razors, also making journal entries about her 
anguish that, in turn, paved the way to deeper psychotherapy. The outcomes and 
predisposing factors for the other two patients belong somewhere in between these 
two extremes. 
   Such observations suggest that symptom-replacement might be a frequent 
occurrence during the course of development. If so, a number of factors seem 
responsible for such an occurrence. With growth, the body changes and so do its 
psychological meanings. Newer fantasies arise, ego grows, and, in the throes of 
adolescence, super-ego becomes more abstract and softened (6).  Greater life 
experience provides trials for identifications and realignment of ideals. All this 
results in changing symptomotology.  Depending on the balance of libido versus 
aggression in the psychic economy, a symptom can become better or worse or be 
replaced by a parallel symptom. 
   And symptom-replacement can occur as a result of psychotherapy too, of course, 
especially in resident-run clinics, where patients derive psychotherapeutic gains 
largely from ego support, survival of the therapist’s containing capacities (7), and 
inexact interpretations (8).  Indeed, the emergence of a milder symptom in place of 
a more disturbing one might even be a cause of celebration.  This has technical 
significance: when the emergence of a new, but less disturbing, phenomenon can 
be correlated with the subsiding of a parallel, more severe symptom, the technical 
approach should not center upon deconstruction-interpretation. Instead, affirmative 
interventions and provision of ego support for the new compromise formation 
should be the centerpiece of the therapeutic strategy (9).   
Regardless of its context, whether developmental or in psychotherapy, 
symptom-replacement in regards to self-mutilation appears to be a frequent and 
often salutary occurrence.  Keep in mind, however, the data we present here is 
limited. As a result, our hypotheses and speculations must be regarded as tentative.  
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First-Known Hypnopompic Hallucination 
Occurring In-Hospital: Case Report 
 
Paul Ballas, D.O. (PGY2) 
 
 
ABSTRACT 
Despite the high prevalence of hypnopompic hallucinations in the community, 
to our knowledge there are no reports that have been published in the English 
literature of these phenomenon observed by staff in the hospital setting. 
Psychiatric or neurological evaluation often ensues if a patient reports 
hallucinations in other circumstances, but when they are reported in 
connection with sleep, further evaluation is rarely performed because such 
events are common in the general populace.  Our report emphasizes the 
distinction between hypnopompic and hypnagogic hallucination as an ongoing 
feature of life that someone is aware of, which we believe to be the case for 
normal persons who have them, and a similar hallucination occurring for the 
first time in someone who is unaware of it, at least unable to remember it. In 
the latter instance, we suggest careful interview for symptoms of a sleep 
disorder.    
 
Hypnagogic (prior to sleep onset) and hypnopompic (upon arousal from 
sleep) hallucinations are both phenomena that occur in normal people and 
symptoms that are characteristic of narcolepsy (1, 2).  They are a common 
occurrence, experienced by almost everyone at least once and have also been 
shown to be associated with the use or withdrawal from certain medications, 
specifically, tricyclic antidepressants, opiates, and donepezil (3-5). Although 
hypnopompic and hypnagogic hallucinations are generally considered to be normal 
phenomenon, they have increased incidence in several psychiatric and neurologic 
disorders (6).  One study of over 14,000 subjects revealed that people with anxiety, 
depression, or bipolar affective disorder have a two-fold increase in experiencing 
hypnopompic or hypnagogic hallucinations at least once weekly.  The same study 
showed that people with adjustment disorders have a 1.5- fold increase in 
experiencing these phenomenon at least once weekly (6-8).  The notion that such 
phenomena are normal may be part of the reason behind the wide variation in the 
literature with regard to their lifetime incidence (hypnopompic 6-13%, hypnagogic 
25–38%) (4, 9-11).   Over 50 percent of people who experience them have no 
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appreciable physical disorder, substance-abuse disorder, sleep disorder, or other 
psychiatric disorder (12).   
 
CASE REPORT 
F.R. is a 41-year-old African American woman who had been admitted to the 
medical service after one day of shortness of breath and two weeks of dull chest 
pain, night sweats, and a non-purulent productive cough.   She had recently 
completed a 3-week corticosteroid taper and a full course of azithromycin for an 
upper respiratory infection.  The patient had a long history of asthma, 
hypertension, and gastroesophageal reflux.  She also had suffered from Grave’s 
disease in the distant past; hypothyroidism developed later on but has been 
corrected with thyroxin.   The patient was compliant with her outpatient 
medications: levothyroxine, hydrochloro-thiazide, montelukast, Protonix, 
fluticasone/salmeterol, continuous home oxygen, multivitamin, and inhaled 
albuterol. She had no personal or family history of neurologic or psychiatric 
disorders. 
 These medications were maintained, and intravenous corticosteroid was 
initiated.  Albuterol was given every 2 hours by nebulizer. Part of the protocol at 
this hospital for someone receiving nebulizer treatments so often is that physician-
reassessment must take place before each treatment. On the first night, after 
approximately four hours of sleep, the patient was awakened for the second time; 
she promptly sat up in bed, looked at her right arm, and yelled, “There’s blood all 
over my arm!”  The resident physician (one of the authors, P.B.) examined her arm 
and saw only a clean IV placement.  He informed the patient of this, but she looked 
back at her arm and proffered it again saying “Look, can’t you see all this blood?”  
Again the physician reassured her that there was nothing there, the patient sat still 
and allowed herself to be evaluated.  She showed no signs of a formal thought 
disorder or of delusion, and she denied any hallucination apart from feeling and 
seeing blood on her arm. Speech was organized normally.  Neurological exam was 
normal. Respiration remained labored, but after the assessment she went back to 
sleep.   
She was examined several other times over the next day and at no other time 
during the admission did she have any other hallucinations or exhibit any signs or 
symptoms of a neurologic or psychiatric disorder.  When asked about the incident, 
the patient had no memory of the hallucinations although she did remember being 
awakened multiple times. When questioned about her sleep outside the hospital, 
the patient did not know if she snored or had apneic episodes, but did report poor 
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sleep quality (frequent unintentional awakenings) and excessive daytime 
sleepiness.  She was referred to a sleep specialist for further evaluation.  
 
DISCUSSION  
This case shows that even with no history of prior psychiatric or neurologic 
disorders, patients in the hospital can have quite striking hallucinations upon 
awakening.  Given the high prevalence of hypnopompic hallucinations among 
normal persons, it is no surprise many clinicians tend to disregard isolated 
incidences such as the one described.  And yet people who experience unusual 
sleep-related events typically have been aware of them their entire lives.  For 
example, in adults who experience sleepwalking or sleep talking there is a high 
prevalence of these phenomena since childhood (13). 
   We believe it is reasonable to do an in-depth interview specifically for sleep 
disorders in every patient who experiences a hypnopompic or hypnagogic 
hallucination for the first time.  Sleep disorders are common, debilitating 
conditions that often go undiagnosed, yet they increase the risk of substance abuse 
and psychiatric disorders (9, 10, 14, 15).  If the interview turns up symptoms 
consistent with a sleep disorder, often a referral to a sleep specialist will be 
indicated.  
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Note:  The Editorial Board made a special request that the author write this essay, and she 
kindly agreed. 
 
A Kind of Poem for My Friend and Me 
 
Hilary O’Neill, M.D. (PGY4) 
 
 
   Physicians are taught to use technical, objective, impersonal language. Does a 
person lose personhood if she’s described as “a 54-year-old African-American 
presenting with increasing lethargy, frequent crying spells, hopelessness, 
helplessness, plus suicidal ideation”? Or, more condensed even, “a 54 yo AAF w/ 
hx BAD,1.” 
   Coffee in my M-mug, and grief’s palpable. It’s my opinion. I don’t know about 
an afterlife. Watching her die made me think of my end, too. Grief is palpable. 
Nothing’s felt right off: so we’re taught. I went to work next day. What else is to 
be done? Stop? I could see myself cold and callous: I’m training myself to be 
professional. I’m a doctor. My friend’s dead, nonexistent. L just called: it’s true, 
M’s dead.  
   Apologies. “Sorry for your loss.” Thanks. Shame. Of course I’ll miss her. And 
your excellent care of my friend, thanks so much, Dr Z. Goodbye. A bunch of us 
read Joyce aloud together in her room. Talked of our love of her company as she 
went right on dying. We were opposed to it, but not to her wish, for it was her 
wish. No relatives there; none had been called, none. She trusted us, her friends, 
our band of eight. We followed her commands. Those things of hers I wanted, like 
the Chinese tea chest; but I didn’t get it: another and better friend put in her claim. 
How could she? How could she not know what it meant to me. Well… “I never 
said I want that!” I wonder if M might have thought we went for the spoils before 
she was cold, even. My grandmother used to say, “Would you be in my grave as 
quick as you’re in my chair?” Marking territory, homo sapiens finding her way 
home. I held her hand thinking it might be, just could be, the last breath: she and 
me. 
   Can I know how another feels? Feel yourself in another’s shoes. Can’t happen, of 
course, if the other isn’t feeling. My life progresses, and my attitude about you 
does, too. Family trees get bigger, leaf out. I mourn all the changes, losing 
childhood even as I get the college of choice. 
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   I’m lonely a year and a day after M died. I look around for her business card, call 
the old number. Lo! Her voicemail still works; I say I miss her a lot. Voicemail for 
the dead. I feel better. Therapy is messaging the dead.  
   I’m vague about existentialism, feels like nihilism. I used to read Jean-Paul 
Sartre. Didn’t occur to me then there are times for meaning and times for 
meaningless. It’s grey in the tunnel: grey at the end, too, maybe. Not winning wars 
but living lives. The Oedipal phase, triangulation; Shakespeare and the web we 
weave; triangles, lines, family trees, missing the forest for the trees. Me, you, me, 
God, existentialism; I, my aunt, I, my grandmother (which?); mothers, fathers, 
mine? 
   Last night I read old journals I’d kept in college, crying, crying: all this way, all 
this way since then, and I still say the same things to myself. My friends, now in 
memory, seem more distinct than they were then, on paper. Scary. Still, it’s my 
handwriting; yes, it is. I don’t remember now each one I wrote about then. I loved. 
I got angry. Ill-understood passions. Go on. Apologize later, cut and run, stay; be 
happy. Combat rock, Clash; is it a jagged little pill? For music soothes the savage 
beast; others it lulls to dreamland. The universals: music, dancing, celebrating, 
mourning. The custom of the uncustomary. What sense is there in waking (one is 
as in “I went to the wake”) the dead? I think wakes are sad and celebratory, for the 
life that’s gone and the life going on. I’ve been to a couple. Not unhappy, not 
happy. The meaning is not all about being happy, for which there’s neither pill nor 
secret. (Only two sure things, says Poor Richard.) Our Declaration guarantees us 
the pursuit not the capture of it. Nor is the meaning all sad, although sad has a big 
role in the thing; maybe there’s a pill for that. Not for me, though, given my natural 
gift already of it. I used to like math, thinking it had a lot of the answers: you got 
them or not. Then I liked literature: a study of people in their time by someone in 
it, their time, with them. I love psychiatry; I love medicine; I love the black, white, 
and grey of them. Points, so many, many points, of view. Right and wrong and 
happy and sad and lines and triangles and enviously or jealously and Latin and 
English or Greek and English or English and English and so forth. 
   Once I wanted to be a veterinarian. My brother sneered, “You want to be a 
doctor because it’s the most prestigious!” I cried and cried. Can’t be true. “You 
don’t know anything about me! I want to help dogs and cats and hamsters.” Or was 
it true? I thought then prestigious was a bad word, one I could never know and 
therefore bad. Makes me laugh now. Not the word being bad but the way he said it. 
Maybe he was explaining something. Maybe big brothers are not so… 
   People ask me if 40’s really bad. No. Twenty nine was bad, 39, too. I hope I get 
to know about 49.  
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   Is my green like yours? My blue your blue. Yellow’s like sunshine, yellow’s the 
streak on my back. Red is my fury and that flapper’s dress, I imagine. ROYGBIV 
or the rainbow? Is there no word rhyming with orange? I live alone, don’t I? With 
somebody or everyone else?  
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Note:  The Editorial Board made a special request that the author write this essay, and he 
kindly agreed. 
 
Mourning 
Salman Akhtar, M.D. 
 
   The mere mention of the word “mourning” floods the mind with visions of tears 
and funerals and sounds of wailing and sobbing.  Images of crying men and 
women, rituals of cremation, or of a body being lowered into a freshly dug grave, 
and tear-soaked words of condolence are among our immediate associations to the 
word.  That it should be so is understandable, for loss of a loved one by death is the 
most potent trigger of the emotional reaction called mourning. 
   Used in a broader fashion, the term “mourning” also refers to the chain of 
sentiments aroused by any loss, big or small (1).  This can range from the loss of 
physical health to that of material wealth. Surgical amputation of a limb can stir up 
a mourning reaction just as one’s car being stolen can. Less dramatic events also 
have the potential of mobilizing the emotional sequence associated with mourning. 
A missed appointment with an out-of-town friend, a misplaced Montblanc pen, and 
an unexpectedly bad result in a college admissions test are all capable of causing 
us to mourn.  
 
MANIFESTATIONS AND VARIABLES 
   Such a broad conceptualization of mourning has commonalities with its narrower 
usage. In either instance, mourning comprises of a set of emotions that unfold over 
time when one is faced with a loss (2-4). Shock and disbelief (“But I met him just 
last week and he appeared fine!”) are the immediate responses. These are soon 
replaced by emotional pain and a desperate sense of longing. Depending upon the 
gravity of the loss, there might be physiological disturbances accompanying this 
stage. Pacing, sighing, clutching one’s chest, pulling at hair, rubbing hands, loss of 
appetite, and disturbed sleep are often evident. As time passes, the turmoil seems 
to settle. The lost person is talked about in exalted ways and all his or her 
blemishes are glossed over; a lost object is an idealized object, mused Freud in his 
seminal paper “Mourning and Melancholia” (5). A mentality of bargaining also 
sets in: “Had I only done this or that, this loss might not have happened”.  Fleeting 
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moments of self-blame appear, although sustained feelings of guilt are not typical 
of ordinary grief. More often one encounters irritability and even anger at the 
occurrence of the loss in the first place. Sooner or later, this too passes. A sense of 
profound aloneness and sadness now takes over. The bereaved finds himself or 
herself fluctuating between heartache, pining for the departed one, dull 
indifference, and the dawn of resigned acceptance of the changed life situation. 
Gradually the rays of hope appear on the psychic horizon and the potential space 
for a substitute begins to open up. The night, it seems, is turning into day. 
   Lest this description appear too schematic or stylized, let me hasten to add a few 
caveats. First, grief comes in waves. It waxes and wanes.  Just when recovery 
seems at hand, one is hit by a fresh upsurge of sorrow. Grief is hardly a linear 
process. The phases described here are useful largely for didactic purposes; human 
experience is always more complex than a catalogue of symptoms.  Second, no 
mourning is ever complete and, by implication, no lost object of our affection is 
ever totally given up. It only is moved to a different place in one’s heart. The pain 
diminishes, to be sure, and emotions do not get readily mobilized. The wound turns 
into a scar but the story remains. 
   A third caveat pertains to the fact that mourning is a process that takes its own 
time; it takes, for instance, about two years to recover reasonably from the loss of a 
truly loved one or from the breakup of a serious romantic relationship. The 
process, like the healing of a bodily wound, cannot be rushed. However, it can be 
delayed if certain complicating factors happen to be on the scene.  Mourning over 
death, for instance, is prolonged if the death was unexpected, occurred in violent 
circumstances, was the result of suicide, and if the death left many unsettled 
accounts, so to speak, between the deceased and the bereaved. Moreover, the 
greater the impact upon the day-to-day reality of the bereaved, the harder it is to 
resolve the grief. The sudden death of a wage-earning head of a household is thus 
more difficult to mourn than the passing away of an elderly grandmother who was 
long-suffering from terminal cancer. 
   Mourning over the death of a child is profoundly difficult, if not utterly 
unfathomable. Not only is the occurrence contrary to the natural order of things 
(e.g., grandparents die first, then parents, then children, and so on), it is tantamount 
to a murder of dreams and hope for the future. Parents are left with the burden of 
“survivor’s guilt” and find grieving to be a life-long nightmare. The pain is greater 
when the offspring lost happens to be an adolescent. Having brought the child to 
the threshold of adulthood and then to lose him or her is truly devastating.  The fact 
that parents are often at cross purposes with their teenage children further 
complicates mourning such a loss. 
 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  48 
COMPLICATED GRIEF 
   When grief does get stuck or complicated, the manifestations of ordinary 
mourning get prolonged over time. The tendency to become teary, feel that the 
deceased is not really dead, or both, normally experienced for a few days or weeks, 
now extends over months and years. The language changes associated with the 
acceptance of death (e.g., “Uncle Elvin is fond of sweets” changing into “Uncle 
Elvin was fond of sweets”) get delayed and the dreams typical of early mourning 
(e.g., seeing the dead person alive, rescuing him or her from a life-threatening 
situation) continue long past a first few months. 
   More significantly, new symptoms appear. The most important among these is a 
peculiar attitude about the physical possessions of the deceased. Under ordinary 
circumstances, things left behind by someone dead are (unknowingly) divided into 
three categories: things that are thrown away (e.g., a toothbrush, socks), things that 
are given away to the poor (e.g., old clothes, shoes), and things that are kept and 
passed on as family heirlooms (e.g., jewelry, diplomas, private journals, unfinished 
manuscripts).  Moreover, this disbursement is neither too quick nor too delayed; it 
usually takes a few weeks to a few months. In complicated grief, however, one 
notices a disregard for time in this context. One either gets rid of the deceased’s 
things immediately (in a magical attempt at denying the significance of what has 
just happened) or hangs onto them forever, finding oneself haplessly unable to 
discard these items. 
   Another development is that things that ought to have been thrown away (e.g., 
dentures, old underwear, a glass eye, a half empty bottle of cold cream) are kept 
and, strikingly, held onto in a very strange way. They can neither be used nor 
thrown away. They cannot even be seen. Looking at them stirs up extremely 
painful emotions of anxiety, pain, and sadness. These things no longer remain mere 
physical artifacts; they become what Volkan has called “linking objects,” i.e., 
things that connect the bereaved with the deceased in unspoken and mysterious 
ways (6). 
   In light of this, it is not surprising that the deceased’s grave becomes a nidus of 
complex feelings on the part of the bereaved. In normal grief, the feelings one has 
towards a loved one’s grave include tender respect and a peculiar mixture of 
wistfulness and a sense of reunion. Visits to the grave occur around the anniversary 
of the death, religiously dictated occasions, and when new members get added to 
the family via weddings and births (7); over the course of time, the frequency of 
such visits diminishes.  However, when grief has become complicated, the grave 
acquires greater emotional charge. One either avoids visiting the grave altogether 
(and even forgetting its location) or becomes “addicted” to it, going there again 
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and again. A displaced form of this is the phenomenon of “obituary addiction” (6), 
whereby an individual with unresolved grief feels compelled to check out the 
obituary section of the newspaper every day. Not finding the name of a loved one 
who has died long ago provides an unconscious reassurance; it is almost as if that 
person is still alive.  
   One thing this description leaves unaddressed is the cause or, to be accurate, the 
causes, of a grief remaining unresolved. Certainly the depth of attachment one has 
with the deceased and the external and internal jagged edges left over by his or her 
departure contribute to the difficulty in mourning. What, however, goes contrary to 
common sense is that unresolved aggression, if not actual hostility, towards the 
deceased plays a significant role in "freezing" the process of grief. The dynamics 
of this are as follows. When there are unspoken hostile and destructive affects and 
fantasies directed at someone who dies, letting him or her go becomes tantamount 
to “killing” him or her; this results from the condensation and telescoping of the 
repressed anger with the reality-dictated necessity of the aggression implicit in 
moving away from an object. 
 
ASSESSMENT AND TRIAGE 
   Since, regardless of specialty, every physician comes into contact with situations 
of grief and mourning, it is important to spell out some essentials of evaluating an 
individual in such circumstances. First and foremost, upon hearing that someone’s 
father or mother or brother or sister or son or daughter has died, the physician must 
not restrict his or her attention to the medical aspects of the occurrence. Questions 
must be asked about the expected versus sudden nature of the death, the 
circumstances surrounding it, and the impact that this death has had upon the 
bereaved’s day-to-day existence. Next, one should inquire about the funeral and 
explore the degree to which the bereaved participated in it. The fate of the ashes (if 
the deceased was cremated) or the location of the grave and the emotions that it 
arouses (if he or she was buried) should also form a focus of gentle but firm 
inquiry. The same applies to the physical possessions of the deceased. How quick 
or how delayed was their disposition? What objects are in the bereaved’s 
possession and what sort of feelings are attached to them? Raising such questions 
would allow a glimpse into the progress or blockage of mourning processes. As 
this conversation is taking place, the physician must also make a mental note of the 
changes in language that occur with a deeper acceptance of someone’s death (see 
above). 
   While known to most physicians, one simple fact can hardly be overemphasized: 
normal grief does not require medical intervention. It is, by definition, a normal 
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process. The attitude that all human suffering is not illness must be maintained; 
some pains are integral to life. This does not mean that individuals in this state of 
normal grief might not end up at a physician’s door. When this happens, curiosity 
should be directed at the lack of social and familial support that has led to 
“medicalizing” a normal process. Parallel to such investigation, the clinical 
approach should consist of empathic remarks, imparting of information regarding 
the nature of normal grief, and a relatively hands-off policy, coupled with 
reassurance of availability should matters become more difficult. If, however, there 
is growing evidence that the grief is becoming complicated (prolonged emotional 
distress, unchanged language, difficulty disposing the deceased’s physical 
possessions, and so on) then active therapeutic interventions do become necessary. 
        
TREATMENT 
   The foregoing has implications for the sort of help one needs to offer to those 
with unresolved mourning.  Listening to their anguish must, of course, be 
respectful and empathic; loss, after all, is not a pleasant affair. The therapist, 
regardless of whether he or she is in the mental-health field or not, should allow 
ample psychological space for the bereaved to elaborate their story. It is advisable 
to not meddle too much with sharp, intellectual comments. What the suffering of 
grief needs most is "witnessing" (8). Listening patiently and making occasional, 
brief, and affirmative remarks which demonstrate that one understands the pain of 
the patient is generally sufficient. The therapist may help the patient to talk in 
greater detail and encourage the bringing in of the deceased's photographs for the 
therapist and the patient to look at together. This would facilitate the emergence of 
hitherto repressed memories and release pent up emotions.  
   Such credulous listening and affirmative stance should, however, not eclipse a 
certain amount of therapeutic skepticism. In listening to someone with pathological 
grief, one must keep one's "third ear" open for the verbal and nonverbal cues of a 
hostile attitude in the patient towards the deceased (9). Such hints and allusions 
should be gathered silently at first. In other words, the tragic motif of grief must be 
allowed to run its course before one begins to point out that the patient has actually 
been somewhat ambivalent about the deceased. It is only with the conscious 
recognition and acceptance of negative feelings towards the dead person that the 
patient can fully come to grips with his true psychic reality. This step is necessary 
for the proper resolution of grief. 
   A less known technical ingredient of "re-grief therapy" (10, 11) is the use of 
linking objects described above. The therapist not only encourages the bereaved to 
talk more and more openly about his or her feelings of loss but also encourages 
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him or her to bring “linking objects” to the office.  Encountering them, touching 
them, holding them, and reminiscing about them (and, through these, about one’s 
complex feeling toward the lost person) helps thaw the frozen grief. That inanimate 
objects should help revive and resolve emotional reactions about someone who 
himself or herself has now become inanimate is an amazing paradox that, in the 
midst of tears, can bring a smile of gratitude to our faces.  Such, as they say, is life! 
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Neuroleptic Malignant Syndrome, with 
Attention to Its Occurrence with Atypical 
Antipsychotic Medication: A Review 
 
Sarah Guzofski, M.D. (PGY2), Ruben Peralta, M.D.  
 
 
ABSTRACT 
The neuroleptic malignant syndrome (NMS) is an idiopathic, life-threatening reaction to 
antipsychotic medication.  NMS was traditionally attributed to potent dopamine 
antagonism of typical antipsychotics, but cases of NMS have now been reported for each of 
the newer antipsychotics.  When NMS is caused by a newer, atypical antipsychotic the 
presentation differs somewhat; fever, rigidity, and, possibly, death may be less frequent.  
Diagnostic features, predisposing factors, and treatment are discussed, as is the important 
matter of reinstituting antipsychotic treatment.  
  
   Neuroleptic malignant syndrome (NMS) is an idiosyncratic, life-threatening 
reaction to antipsychotic medication, characterized principally by delirium, fever, 
autonomic instability, and muscular rigidity (1). Most cases occur within a month 
of starting the medication, two-thirds within the first week. NMS develops in 0.02-
2.44 percent of patients who are prescribed antipsychotics (2-4); NMS may occur 
even when doses are in the therapeutic range; the risk is somewhat greater with 
rapid dose escalation and with parenteral administration.    
   Hyperthermia, delirium, autonomic instability, and extrapyramidal symptoms in 
a person treated with antipsychotic medications should prompt consideration of 
NMS.  Classically, the extrapyramidal symptoms of NMS manifest as “lead pipe” 
rigidity of the limbs; other extrapyramidal signs, such as tremor, and cogwheeling, 
may be present.  The muscular rigidity leads to rhabdomyolysis, which can in turn 
result in renal failure.  A wide range of mental status presentations are possible, but 
patients are most often mute and stuporous.   Laboratory findings include 
leukocytosis (most often 10-20,000, thought to be a stress response) elevated 
creatine kinase (can reach 100,000), hypocalcemia (from muscle sequestration of 
calcium), moderate elevations of LDH, AST and ALT, and elevated serum 
osmolarity from dehydration.  An EEG may show generalized slowing, consistent 
with delirium (5).  Symptoms generally develop over 24-72 hours and, in 
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uncomplicated cases, the mean duration of symptoms is 13-15 days, longer if 
caused by a depot medication (2). Serious complications are possible, including 
renal failure, thromboembolism, respiratory failure from chest wall rigidity, 
aspiration pneumonia, and arrhythmia (5).  
   DSM IV-TR criteria (6) for diagnosing NMS are in Table 1.  A slightly different 
set of criteria, proposed by Levenson (5), is also commonly employed (Table 2).   
 
 
Table 1. DSM IV-TR Diagnostic Criteria for NMS  
Severe muscle rigidity and elevated temperature associated with the use of neuroleptic 
medication as well as 2 or more of the following 
   Diaphoresis 
   Dysphagia 
   Tremor 
   Incontinence 
   Changes in level of consciousness ranging from confusion to coma 
   Mutism 
   Tachycardia 
   Elevated or labile blood pressure 
   Leukocytosis 
   Laboratory evidence of muscle injury 
 
 
Table 2.  Levenson’s criteria for the diagnosis of NMS* 
Major criteria   
        fever  
        rigidity  
        elevated creatine kinase (CK) 
Minor criteria  
        tachycardia  
        abnormal blood pressure  
        altered consciousness 
        diaphoresis  
        leukocytosis  
* 3 major criteria, or 2 major and 4 minor criteria, are required for diagnosis   
 
 
   In the differential diagnosis, infectious, metabolic and neurologic conditions 
should be considered, depending on associated clinical features (Table 3). An 
interesting debate has centered around the similarities and differences between 
malignant catatonia and NMS.  These two conditions, affecting a similar patient 
population, can be so similar in their presenting features that some have argued 
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that they are variants on a spectrum (7).  Because NMS, malignant catatonia, and 
serotonin syndrome are difficult to distinguish on symptomatic presentation alone, 
medication history, behavioral prodrome, and timeline of symptom-evolution will 
be critical to making a diagnosis.   
 
Table 3.  Differential Diagnosis 
Diagnosis Suggestive Clinical Features, Indicated Lab Testing 
Infectious: meningitis, 
encephalitis, bacteremic sepsis 
Lumbar puncture.  Consider blood and urine cultures 
depending on overall clinical picture 
Metabolic: thyrotoxicosis, 
pheochromocytoma 
Check TSH, urine catacholamines and metanephrines 
Neurologic: nonconvulsive 
status epilepticus, postictal 
state 
EEG  
Drug intoxications: MDMA, 
cocaine, amphetamines 
Urine toxicology 
Serotonin syndrome Associated with gastrointestinal signs and symptoms 
(hyperactive bowel sounds, diarrhea, vomiting), myoclonus, 
hyperreflexia 
Lithium toxicity Check lithium level. Myoclonus, hyperreflexia, tremor 
Central anticholinergic 
syndrome 
Dry, flushed skin, diminished sweating, urinary retention, 
dilated pupils 
Malignant hyperthermia Exposure to halogenated anesthetics 
Malignant or lethal catatonia Associated with hyperpyrexia, rigidity, akinesia.  Review 
behavior changes over previous weeks.  May be preceded 
by emotional withdrawal, anxiety, agitation, stereotypies, 
posturing, waxy flexibility, mutism. 
Neuroleptic-induced heat 
stroke 
Suggestive history: warm environment, abrupt onset, no 
extrapyramidal signs, may have absence of diaphoresis if 
anticholinergic properties interfere with sweating. 
 
 
Risk Factors 
   NMS is an idiosyncratic reaction and cannot be predicted, but there are some 
identified risk factors.  Young age, male gender, dehydration, agitation, rapid dose-
escalation, and intra-muscular administration increase the risk (5,8). Prior NMS 
increases the risk for future episodes.  There is some evidence for an association 
between NMS and the following (9,10): concurrent lithium treatment, poorly 
controlled extrapyramidal symptoms, patients with affective disorders, iron 
deficiency, poor nutrition, environmental heat load, catatonia, and those drugs that 
are more potent dopamine-2 (D2) antagonists.   
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Pathogenesis 
   The pathogenesis of NMS is unknown.  Observation that NMS occurred with D2 
blocking agents lead to the hypothesis that D2 blockade in various regions of the 
brain explained the presentation: D2 action in the reticular activating system could 
cause changes in level of consciousness;  D2 blockade in the nigrostriatal pathway 
could cause rigidity; D2 blockade in the hypothalamus could account for 
autonomic instability and impaired heat dissipation, thus hyperpyrexia from the 
combination of hypothalamic dysfunction and muscle rigidity (9-11). This theory 
is now challenged since atypical antipsychotics, with their lower D2 potency, are 
reported to cause NMS.      
 
NMS and Atypical Antipsychotics 
   There have been reports of NMS attributed to each of the atypical antipsychotics 
and all of these medications are listed in the NMS Information Services’ Registry 
(9).  The rates and presenting symptoms of NMS in typical versus atypical 
antipsychotics have not been directly compared (12), but some observations are 
possible from available information.  Of the 55 “probable” or “definite” cases of 
NMS reported to the Neuroleptic Malignant Syndrome Information Service 
between 1998 and 2002, 31 patients (56%) were on a typical antipsychotic; 24 
patients (44%) were on an atypical antipsychotic (13).   Cases of NMS have been 
reported with even the least potent D2 antagonist, clozapine (2,14). 
   NMS owing to atypical antipsychotics has possibly a different presentation 
compared with the traditional syndrome: less extreme CK and temperature 
elevations and less common and milder rigidity (14,15).  A 2003 review of 68 
reported cases of NMS from atypical antipsychotics found that the mean peak CK 
was 5958 and the mean maximum temperature was 38.8.  Seventy eight percent of 
patients had extrapyramidal symptoms.  Twelve of the 68 required intensive care 
and 3 patients died (2).  This mortality rate is less than that historically reported in 
NMS (11,16). Perhaps resulting from improved supportive care, mortality in NMS 
is declining overall: from 76% prior to 1970 to 11% in a 1989 study, (2,11,17).  
 
Treatment   
   If NMS is suspected, immediately discontinue all antipsychotic medication, as 
well as other D2 blocking agents.  A medical work-up should be initiated (see 
above): NMS is a diagnosis of exclusion.  Supportive care is the mainstay of 
treatment for NMS and it should occur in a setting in which  blood pressure, 
cardiac rhythm, and pulse-oximetry can be continuously monitored.   Autonomic 
instability may manifest as hypertension, hypotension, tachycardia, or cardiac 
arrhythmia.  Chest wall rigidity can compromise respiration sufficiently to require 
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intubation; intubation may also be indicated for severe aspiration pneumonia.  
Urine alkalinization and adequate support with intravenous fluids may prevent 
renal failure from myoglobinuria (18). Hyperthermia may require a cooling 
blanket.  Because hyperthermia in NMS is not mediated by pyrogens, antipyretic 
medications are generally not helpful (1).  Laryngeal dystonia, dysphagia, 
respiratory distress, or delirium may preclude oral intake, so intravenous fluid and 
parenteral nutrition may be needed (1). Prophylactic measures for deep venous 
thrombosis and frequent repositioning will decrease the likelihood of 
complications from rigidity and prolonged immobility (5).  The medication list 
should be reviewed: anticholinergic agents or other drugs that interfere with heat 
dissipation should be discontinued  (1). 
   Medication may hasten response to supportive therapy and decrease mortality 
(19,20), but controlled clinical trials do not exist, and drug studies that are 
available have not always shown benefit (21).  The two most commonly used 
pharmacologic interventions are bromocriptine, a central dopamine agonist, and 
dantrolene, which facilitates skeletal muscle relaxation via calcium release from 
the sarcoplasmic reticulum (5,9,22).  Dantrolene is available in a parenteral form; 
bromocriptine can only be administered orally.  Symptoms of NMS sometimes 
return if treatment is discontinued before complete clearance of the offending 
medication, so, if bromocriptine, dantrolene, or both are utilized, treatment should 
be continued for ten days beyond the resolution of symptoms, or for 2-3 weeks if 
the offending agent has been an extended release depot antipsychotic (5). 
   Oral or intravenous benzodiazepine, the mainstay of early treatment of catatonia, 
may decrease fever and rigidity in NMS, in addition to treating agitation (1). 
Respiratory status should be monitored. Positive results have been reported with 
diazepam (23) and lorazepam (24).  
   Electroconvulsive therapy (ECT) is another treatment option and may decrease 
hyperpyrexia, diaphoresis, and delirium, possibly by modulating dopamine activity 
in the brain.  Onset of response, on average, is after 4 treatments (12).  ECT should 
be considered especially for patients who have not improved after 48 hours of 
pharmacologic treatment, if it is not clear whether the cause of the symptoms is 
neuroleptic malignant syndrome or malignant catatonia, and if the underlying 
psychiatric diagnosis is a mood disorder (12,25-28).  
 
Antipsychotic treatment after NMS  
   Patients with a history of NMS are likely to require future antipsychotic 
treatment. The estimated risk of developing NMS again with repeat exposure to a 
D2 blocker is 30%, and the risk of mortality from subsequent NMS episodes is 
estimated to be as high as 20%) (13).  Treatment decisions are further complicated 
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by the observation that not all patients will experience a recurrence, even if they 
are treated with the same drug.   
    There are very few formal studies documenting the outcome of antipsychotic 
treatment after NMS.  Several reviews of this topic were written in the late 1980s 
(28-30, 32). For example, Olmstead reviewed 29 rechallenges reported in the 
literature; 13 of the 29 had a recurrence, and 2 of those patients died; the most 
common agent used for rechallenge was the low potency agent thioridazine (13 of 
29 patients, causing 2 recurrences of NMS, one culminating in death) (29). 
Rechallenges that produce recurrence of NMS are reported with a variety of 
medications. Rechallenge at least 2 weeks after the initial episode appears to be 
safer, and recurrence is more likely if high potency medication or high doses are 
used (1).  In a 1989 review, Rosebush and colleagues report that 13 of 15 patients 
with prior NMS experienced no recurrence on rechallenge (30). And two small, 
longer-term reviews found that in a majority of patients who are rechallenged with 
antipsychotic medication NMS does not recur (31,32).   
   Based on these reviews, on the observed risk factors for NMS, and on theoretical 
speculation about pathogenesis, we come to the following as recommendations for 
reinstituting treatment after the first episode, with the understanding that the 
evidence supporting them is limited. Weigh risks, benefits, and alternatives to 
antipsychotic medication. If alternatives are poor and the benefit outweighs the 
risk, restart antipsychotic after a 4-week waiting period following the resolution of 
the episode. Begin with a low dose, advance slowly toward the target dose, and 
choose an agent with low D2-nigrostriatal affinity (an atypical or a low potency 
typical).   Monitor carefully for fever, autonomic instability, mental status change, 
extrapyramidal symptoms, and dehydration. Serial measurements of white blood 
cell count and CK are warranted. Agitation should be treated aggressively with 
benzodiazepine, since agitation increases the risk for NMS.  Adjunctive treatment 
with a mood stabilizer, antidepressant, or both for affective symptoms may 
minimize, possibly, the required dose of antipsychotic (22,29,33). Velamoor has 
suggested considering prophylaxis with amantadine or bromocriptine (22).    
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Editorial: NMS, and Why We Should Call It 
(Malignant) Catatonia 
 
Robert Arnold Johnson, M.D. (PGY4) 
 
 
   The review in the current issue by Guzofski and Peralta, “Neuroleptic Malignant 
Syndrome, with Attention to Its Occurrence with Atypical Antipsychotic 
Medication: A Review,” reminds me of the influence of a name. I am thinking here 
of the name, “neuroleptic malignant syndrome” (NMS), which was coined by 
Delay in 1960, following reports of “catatonic-like” states resulting from 
phenothiazines, and popularized through an influential review by Caroff in 1980 
(1, 2).  
   A very similar syndrome, recognized as an advanced (excited, lethal, malignant, 
pernicious) form of catatonia had been described well before the advent of the 
typical antipsychotic medications. And catatonic features often are an overt feature 
of NMS (3-5). In addition, simple catatonia is recognized as a risk factor for NMS 
if typical neuroleptic is given (5). Even so, the name of NMS took on a life of its 
own, a meme, we might say, that began to spread from one psychiatrist’s mind to 
another independently of the meme(s) for catatonia, despite the efforts of some to 
stem the tide (3). I offer as proof of this last sentence two first-hand observations. 
First, I find that few of my peers are aware of a link between, or similarity of, 
NMS and malignant catatonia (MC). Second, Doctors Guzofski and Peralta did not 
include much mention of MC in their original submission. And, I suspect, nothing 
unusual at all resides in either of these observations. A very large number of 
psychiatrists and psychiatry residents do not realize NMS and MC are linked 
concepts, that’s my guess. I have been luckier myself. Two of my mentors when I 
was a PGY2 on the Consultation-Liaison rotation here at Jefferson, Dr. David 
Lynn and Dr. Dimitri Markov, taught me about MC and encouraged me to dig into 
its literature; as I did that, I learned about its link with NMC. And for that I have 
most to thank Dr. Max Fink and his colleague, Dr. Michael Alan Taylor (6, 7). 
They are not the only, or even the first, authors to speak of a link between MC and 
NMS (3), but Dr. Fink, especially, has been the most declamatory on the topic, the 
one most emphatic that the matter of language, the matter of the name, has a lot to 
do with how we clinicians behave.  
   His point of view is that NMS is a variant of, or a subtype of, MC: MC that 
happens to have been triggered by an antipsychotic medication. (The same is true, 
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he believes, of serotonin syndrome: a subtype of MC, one that has been triggered 
by serotonergic excess.) And this view has a highly practical implication, namely, 
that treatment that is effective for catatonia should not be withheld from those 
suffering from NMS. He is thinking of benzodiazepine (lorazepam is used most 
often) and, should that medication prove ineffective within a few days, 
electroconvulsive therapy (ECT). The dose of lorazepam that is required is often 
quite high, so the schedule by which it is advanced will need to be aggressive 
(taking care not to produce oversedation or respiratory compromise, of course); it 
can be given parenterally, and should be in some instances (8). 
   So, having brought the memes of MC and NMS together in your mind, you 
become vigorous in the application of benzodiazepine. But it is in the early use 
(“early” in a relative sense) of ECT that your thinking is most changed by 
comparison with your thinking had the two memes remained estranged. And that’s 
because the NMS meme, as an isolated thing, does not lead to thinking of ECT (or 
benzodiazepine) early on. It is modeled on another meme (by “meme”—maybe I 
should be speaking of a whole family of them—I mean, of course, a word or 
phrase or idea that appears to spread from mind to mind in the Dawkins sense, as a 
selfish gene might, were it possible for a gene to spread from mind to mind), that 
of malignant hyperthermia (MH), which brings forward first the idea of supportive 
care, especially with regard to control of body temperature and fluid volume, and 
this, of course, is a fine outcome even were MC and NMS two separate things. 
And next among the weapons summoned up by the NMS meme(s) is the drug 
dantrolene (a direct-acting muscle-relaxant that affects calcium flux from the 
endoplasmic reticulum), also bromocriptine (a dopamine agonist to fix the 
hypodopominergic state that the neuroleptic caused), amantadine (another 
dopaminergic drug), or both. And uncontrolled but careful clinical studies provide 
good support for the use of dantrolene and dopaminergic drugs in NMS (1, 5). It’s 
not that their use is to be avoided, it’s that ECT should not be put off long if they, 
as adjuncts to benzodiazepine, have not relieved the disorder within a few days. 
And Dr. Fink’s point is this: ECT is likely to be put off too long if the concepts of 
NMS and MC are not linked in the clinician’s mind, brought together in the one 
idea that the former is a special subtype of the latter. Two excellent books on 
catatonia, both published recently, support this opinion and document its history 
(9, 10). 
   No randomized studies of ECT in MC or NMS exist, but clinical experience with 
its good effectiveness in these conditions, which I, following Fink and several 
others, shall link together as one, is fairly extensive (1, 2, 5, 6, 11-14). It appears to 
be safe generally, but at least two patients have died as a consequence, so some 
caveats are in order. First is that neuroleptic must be stopped as far in advance of 
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the procedure as possible (which should have been the case at the time of diagnosis 
anyway), as the two deaths mentioned were both in patients in whom neuroleptic 
had been continued (15). The neuroleptic in these cases was a typical one, but the 
caveat almost surely should extend to the newer, atypical antipsychotics also. 
Second is that succinylcholine should be avoided as the paralyzing agent for ECT 
if at all possible; this agent is known to predispose to abrupt hyperkalemia 
(possibly the mechanism of death for the two cases mentioned), and conditions 
favoring hyperkalemia are already extant in the situation (muscular injury from 
rigidity and high body temperature; possible renal compromise from myoglobin-
uria and extracellular volume depletion; possibly a direct potassium-releasing 
effect of ECT on skeletal muscle). The third follows from what has just been said: 
serum potassium should be monitored very closely and great care should be taken 
to ensure that extracellular volume has been repleted by adequate intravenous 
supple-mentation (16). 
   Thinking of MC, NMS, and serotonin syndrome (SS) as variations on the same 
theme, that of catatonia, makes it easier for me to remember how they present, 
mainly as the same picture with some interesting differences: the excited, 
prodromal phase may be missing and muscular rigidity earlier in NMS; 
gastrointestinal distress, and maybe myoclonic seizures, more prominent in SS. 
Seeing the one family makes it easier to pick up the distinctions among its 
members. And, speaking of families, what a large number of conditions has been 
reported to cause catatonia! Most of the reports are of the “benign” (simple, 
retarded) form (BC), but I see no reason to presume that a condition capable of 
causing BC could not also cause MC, as the latter may occur as an “advanced” 
stage, or complication, of the former. I have gathered the conditions that I have 
come across in the literature into two tables. The citations for these, in many 
instances, are in the articles or books cited in the References section.  
 
 
Table 1. Psychiatric Predispositions to Catatonia  
  mood disorders          
 mania or depression: ~ 50% of catatonias; 25-50% of all catatonics are manic  
 schizophrenia & other psychoses         
 ~ 15% of catatonic adults; higher % in children 
  autism spectrum disorders  
         obsessive-compulsive disorder (at least the PANDAS form) 
         dissociative disorders/hypnosis 
 narcolepsy        
 periodic catatonia (a rare familial form, maybe autosomal dominant) 
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Table 2. Medical Predispositions to Catatonia 
 (Approximately 25% of catatonias have no psychiatric cause)      
  
Neurological          
• Von Economo’s encephalitis 
• HIV 
• Chagas disease (acute) 
• Lyme disease 
• Herpes simplex 
• GPI (CNS syphilis) 
• subacute sclerosing panencephalitis  
• acute disseminated encephalomyelitis 
• seizure disorder (esp in children), incl 
postictal 
• postmalarial syndrome, w/ psychosis 
• head injury, including subdural hematoma    
• subarachnoid hemorrhage 
• basilar artery thrombosis 
• stroke (often cardioembolic) 
• Sheehan’s syndrome 
• paraneoplastic encephalopathy 
• periventricular diffuse pinealoma 
• tumor of septum pellucidum 
• subthalamic tumor, w/ hydrocephalus 
• alcoholic/Wernicke encephalopathy   
• multiple sclerosis    
• Parkinson’s disease  
• progressive supranuclear palsy 
• dementia with Lewy bodies 
• familial cerebellar-pontine atrophy 
• hereditary spinocerebellar degeneration   
• tuberous sclerosis    
• Creutzfeldt-Jacob disease    
• bilateral globus pallidus lesions 
• frontal, parietal, or thalamic lesions    
• arachnoid cyst 
 
Systemic 
• SLE     
• FUO  
• TTP     
• Wilson’s disease 
• liver transplantation 
• hepatic encephalopathy 
• uremia 
• diabetic ketoacidosis 
• membranous GN 
• hyponatremia 
• burns 
• staphylococcal infection 
• tetanus 
• tuberculosis  
• infectious mononucleosis 
• typhoid fever 
• PANDAS 
• vitamin B12 deficiency 
• hyperparathyroidism/hypoparathyroidism 
• pheochromocytoma   
• thyrotoxicosis 
• acute intermittent porphyria 
• Addison’s disease/Cushing’s disease  
   
• MEN, 1  
• hereditary coproporphyria  
• carcinoid tumor    
• homocystinuria   
• pellagra                      
• Tay-Sach disease (adult form)  
  
     
Toxic Effect of a Medication or Substance 
• azithromycin   
• ciprofloxacin     
• bupropion  
• venlafaxine   
• clomipramine 
• methylphenidate 
• lithium 
• levetiracetam  
• neuroleptic (NMS) 
• serotonergic (SS)  
• corticosteroid, ACTH 
• fluorides  
• baclofen 
• disulfiram    
• cyclosporine 
• reserpine 
• metoclopramide 
• psilocybin 
• PCP 
• MDMA (ecstasy) 
• opiates 
• mescaline 
• illuminating gas 
• alcohol 
• aspirin (overdose) 
• strychnine     
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Withdrawal from a Medication 
• lorazepam, other benzodiazepine   
• mixed sedative 
• carbamazapine 
 
 
  
• dopaminergic drugs 
• anticholinergic drugs 
• gabapentin 
 
 
 
   Hard to shake off vertigo from simply looking at these tables. Harder still to 
imagine the disorder in the clinician’s mind, were there no unifying idea like 
“catatonia” to bring them together under the one roof: otherwise we would be 
trying to memorize, I suppose, the neuropsychiatric features one by one that each 
was reputed to have caused. And we would have no idea at all how to proceed with 
therapy. As it is, we can know this: the catatonic illness that each and every one of 
these disorders can, on occasion, produce is treated in exactly the same way, 
varying only according to its response to initial therapy, namely, to lorazepam!  Of 
course, with the exception of withholding typical neuroleptic in all catatonias until 
the state is relieved, and withholding any antipsychotic, typical or atypical, in the 
MC variant, it doesn’t hurt to treat the specific predisposition to the catatonic state, 
too, whenever that is possible. Such is the value of a name, the right name. Which 
doesn’t mean the future could not bring a better one, or reveal that we’d be better 
off with more than one, and which names those should be. 
   Just why the two names, NMS and MC, fell apart and propagated separately is 
unclear, to me anyway. It seems that some of the important writers about them in 
decades past, Caroff and colleagues, and Fricchione and colleagues, took distinct 
care to see that separate propagation did not occur. And yet it did. (Which is why 
Dr. Fink has had to come to the rescue.) Perhaps psychiatry contains such variety it 
has trouble keeping its language from splitting into dialects that soon fracture its 
citizenry. Perhaps our textbook editors have under-appreciated the phenomenon of 
catatonia (the topic surely gets short shrift in some), owing to having succumbed to 
addictive properties in the format of the DSM-IV. The latter has an unstable 
placement for catatonia (6), apparently out of loyalty, conscious or not, to the 
outmoded conception that catatonia is mainly a schizophrenic condition. Perhaps 
NMS, flirtatious as it is with the MH meme(s), has biological cachet for those who 
are made anxious by the very subject of psychiatry, which is the mind.  
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